<?xml version="1.0"?>
<dataset>
    <table name="journals">
        <column>id</column>
        <column>issn</column>
        <column>title</column>
        <column>abbr</column>
        <row>
            <value>1</value>
            <value>1549-490X</value>
            <value>The oncologist</value>
            <value>Oncologist</value>
        </row>
        <row>
            <value>2</value>
            <value>1998-4774</value>
            <value>Indian journal of cancer</value>
            <value>Indian J Cancer</value>
        </row>
        <row>
            <value>3</value>
            <value>1876-7737</value>
            <value>Journal of proteomics</value>
            <value>J Proteomics</value>
        </row>
        <row>
            <value>4</value>
            <value>1873-4111</value>
            <value>Maturitas</value>
            <value>Maturitas</value>
        </row>
        <row>
            <value>5</value>
            <value>1474-547X</value>
            <value>Lancet</value>
            <value>Lancet</value>
        </row>
        <row>
            <value>6</value>
            <value>0125-2208</value>
            <value>Journal of the Medical Association of Thailand = Chotmaihet thangphaet</value>
            <value>J Med Assoc Thai</value>
        </row>
        <row>
            <value>7</value>
            <value>1533-4406</value>
            <value>The New England journal of medicine</value>
            <value>N Engl J Med</value>
        </row>
        <row>
            <value>8</value>
            <value>1321-2753</value>
            <value>Monash bioethics review</value>
            <value>Monash Bioeth Rev</value>
        </row>
        <row>
            <value>9</value>
            <value>1752-8062</value>
            <value>Clinical and translational science</value>
            <value>Clin Transl Sci</value>
        </row>
        <row>
            <value>10</value>
            <value>0006-3002</value>
            <value>Biochimica et biophysica acta</value>
            <value>Biochim Biophys Acta</value>
        </row>
        <row>
            <value>11</value>
            <value>1080-6059</value>
            <value>Emerging infectious diseases</value>
            <value>Emerging Infect Dis</value>
        </row>
        <row>
            <value>12</value>
            <value>1567-7257</value>
            <value>Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in
                infectious diseases
            </value>
            <value>Infect Genet Evol</value>
        </row>
        <row>
            <value>13</value>
            <value>1999-4915</value>
            <value>Viruses</value>
            <value>Viruses</value>
        </row>
        <row>
            <value>14</value>
            <value>1931-8405</value>
            <value>AIDS research and human retroviruses</value>
            <value>AIDS Res Hum Retroviruses</value>
        </row>
        <row>
            <value>15</value>
            <value>1464-5351</value>
            <value>Culture, health &amp;amp; sexuality</value>
            <value>Cult Health Sex</value>
        </row>
        <row>
            <value>16</value>
            <value>1473-5571</value>
            <value>AIDS (London, England)</value>
            <value>AIDS</value>
        </row>
        <row>
            <value>17</value>
            <value>1723-2007</value>
            <value>Blood transfusion = Trasfusione del sangue</value>
            <value>Blood Transfus</value>
        </row>
        <row>
            <value>18</value>
            <value>1523-6536</value>
            <value>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow
                Transplantation
            </value>
            <value>Biol Blood Marrow Transplant</value>
        </row>
        <row>
            <value>19</value>
            <value>1945-7197</value>
            <value>The Journal of clinical endocrinology and metabolism</value>
            <value>J Clin Endocrinol Metab</value>
        </row>
        <row>
            <value>20</value>
            <value>1532-2394</value>
            <value>Journal of liposome research</value>
            <value>J Liposome Res</value>
        </row>
        <row>
            <value>21</value>
            <value>1938-5404</value>
            <value>Radiation research</value>
            <value>Radiat Res</value>
        </row>
        <row>
            <value>22</value>
            <value>1942-5473</value>
            <value>Pediatric dentistry</value>
            <value>Pediatr Dent</value>
        </row>
        <row>
            <value>23</value>
            <value>0034-8376</value>
            <value>Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion</value>
            <value>Rev Invest Clin</value>
        </row>
        <row>
            <value>24</value>
            <value>1873-4995</value>
            <value>Journal of controlled release : official journal of the Controlled Release Society</value>
            <value>J Control Release</value>
        </row>
        <row>
            <value>25</value>
            <value>1364-6893</value>
            <value>Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
            </value>
            <value>J Obstet Gynaecol</value>
        </row>
        <row>
            <value>26</value>
            <value>0253-7184</value>
            <value>Indian journal of sexually transmitted diseases</value>
            <value>Indian J Sex Transm Dis</value>
        </row>
        <row>
            <value>27</value>
            <value>1537-6613</value>
            <value>The Journal of infectious diseases</value>
            <value>J Infect Dis</value>
        </row>
        <row>
            <value>28</value>
            <value>1745-5065</value>
            <value>Women's health (London, England)</value>
            <value>Womens Health (Lond Engl)</value>
        </row>
        <row>
            <value>29</value>
            <value>1097-0274</value>
            <value>American journal of industrial medicine</value>
            <value>Am J Ind Med</value>
        </row>
        <row>
            <value>30</value>
            <value>2042-0226</value>
            <value>Cellular &amp;amp; molecular immunology</value>
            <value>Cell Mol Immunol</value>
        </row>
        <row>
            <value>31</value>
            <value>1768-3254</value>
            <value>European journal of medicinal chemistry</value>
            <value>Eur J Med Chem</value>
        </row>
        <row>
            <value>32</value>
            <value>2253-8070</value>
            <value>Revista espanola de medicina nuclear e imagen molecular</value>
            <value>Rev Esp Med Nucl Imagen Mol</value>
        </row>
        <row>
            <value>33</value>
            <value>1439-0531</value>
            <value>Reproduction in domestic animals = Zuchthygiene</value>
            <value>Reprod Domest Anim</value>
        </row>
        <row>
            <value>34</value>
            <value>1423-0380</value>
            <value>Tumour biology : the journal of the International Society for Oncodevelopmental Biology and
                Medicine
            </value>
            <value>Tumour Biol</value>
        </row>
        <row>
            <value>35</value>
            <value>1389-2029</value>
            <value>Current genomics</value>
            <value>Curr Genomics</value>
        </row>
        <row>
            <value>36</value>
            <value>1792-1074</value>
            <value>Oncology letters</value>
            <value>Oncol Lett</value>
        </row>
        <row>
            <value>37</value>
            <value>0974-5130</value>
            <value>Indian journal of pathology &amp;amp; microbiology</value>
            <value>Indian J Pathol Microbiol</value>
        </row>
        <row>
            <value>38</value>
            <value>1532-1827</value>
            <value>British journal of cancer</value>
            <value>Br J Cancer</value>
        </row>
        <row>
            <value>39</value>
            <value>1934-2403</value>
            <value>Endocrine practice : official journal of the American College of Endocrinology and the American
                Association of Clinical Endocrinologists
            </value>
            <value>Endocr Pract</value>
        </row>
        <row>
            <value>40</value>
            <value>1513-7368</value>
            <value>Asian Pacific journal of cancer prevention : APJCP</value>
            <value>Asian Pac J Cancer Prev</value>
        </row>
        <row>
            <value>41</value>
            <value>1934-6638</value>
            <value>Cancer cytopathology</value>
            <value>Cancer Cytopathol</value>
        </row>
    </table>
    <table name="articles">
        <column>id</column>
        <column>indexer_id</column>
        <column>volume</column>
        <column>issue</column>
        <column>pages</column>
        <column>year</column>
        <column>month</column>
        <column>day</column>
        <column>journal_id</column>
        <column>title</column>
        <column>pub_status</column>
        <row>
            <value>1</value>
            <value>PMID24951611</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>20</value>
            <value>1</value>
            <value>Cervical Cancer in Ethiopia: Survival of 1,059 Patients Who Received Oncologic Therapy.</value>
            <value>0</value>
        </row>
        <row>
            <value>2</value>
            <value>PMID24947086</value>
            <value>51</value>
            <value>1</value>
            <value>1-4</value>
            <value>2014</value>
            <value>Jan-Mar</value>
            <value></value>
            <value>2</value>
            <value>Socio-demographic characteristics of cancer patients: Hospital based cancer registry in a tertiary
                care hospital of India.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>3</value>
            <value>PMID24862987</value>
            <value>108C</value>
            <value></value>
            <value>99-109</value>
            <value>2014</value>
            <value>May</value>
            <value>24</value>
            <value>3</value>
            <value>Whole genome identification of C. trachomatis immunodominant antigens after genital tract infections
                and effect of antibiotic treatment of pigtailed macaques.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>4</value>
            <value>PMID24861965</value>
            <value>78</value>
            <value>3</value>
            <value>160-7</value>
            <value>2014</value>
            <value>Jul</value>
            <value></value>
            <value>4</value>
            <value>Cervical cancer in the older woman.</value>
            <value>1</value>
        </row>
        <row>
            <value>5</value>
            <value>PMID24856024</value>
            <value>383</value>
            <value>9931</value>
            <value>1804-5</value>
            <value>2014</value>
            <value>May</value>
            <value>24</value>
            <value>5</value>
            <value>Cervical cancer mortality in India - Authors' reply.</value>
            <value>1</value>
        </row>
        <row>
            <value>6</value>
            <value>PMID24856023</value>
            <value>383</value>
            <value>9931</value>
            <value>1804</value>
            <value>2014</value>
            <value>May</value>
            <value>24</value>
            <value>5</value>
            <value>Cervical cancer mortality in India.</value>
            <value>1</value>
        </row>
        <row>
            <value>7</value>
            <value>PMID24851559</value>
            <value>97 Suppl 4</value>
            <value></value>
            <value>S12-9</value>
            <value>2014</value>
            <value>Apr</value>
            <value></value>
            <value>6</value>
            <value>Prognostic factors of human papillomavirus genotypes of invasive cervical carcinoma: an analytical
                cross-sectional study in lower north-east Thailand.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>8</value>
            <value>PMID24849087</value>
            <value>370</value>
            <value>21</value>
            <value>2032-41</value>
            <value>2014</value>
            <value>May</value>
            <value>22</value>
            <value>7</value>
            <value>Case records of the Massachusetts General Hospital. Case 16-2014. A 46-year-old woman in Botswana
                with postcoital bleeding.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>9</value>
            <value>PMID24844057</value>
            <value>31</value>
            <value>2</value>
            <value>8-9</value>
            <value>2013</value>
            <value>Sep</value>
            <value></value>
            <value>8</value>
            <value>HPV vaccine working in Australia.</value>
            <value>1</value>
        </row>
        <row>
            <value>10</value>
            <value>PMID24841923</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>May</value>
            <value>19</value>
            <value>9</value>
            <value>Human Papillomavirus Vaccination: A Case Study in Translational Science.</value>
            <value>0</value>
        </row>
        <row>
            <value>11</value>
            <value>PMID24960591</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>21</value>
            <value>10</value>
            <value>Long-range effects of tag sequence on marginally stabilized structure in HIV-1 p24 capsid protein
                monitored using NMR.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>12</value>
            <value>PMID24960557</value>
            <value>20</value>
            <value>7</value>
            <value>1163-9</value>
            <value>2014</value>
            <value>Jul</value>
            <value></value>
            <value>11</value>
            <value>Population-Based Analysis of Invasive Fungal Infections, France, 2001-2010.</value>
            <value>1</value>
        </row>
        <row>
            <value>13</value>
            <value>PMID24960396</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>21</value>
            <value>12</value>
            <value>Genetic diversity of norovirus in hospitalised diarrhoeic children and asymptomatic controls in Dar
                es Salaam, Tanzania.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>14</value>
            <value>PMID24960314</value>
            <value>20</value>
            <value>7</value>
            <value>1149-56</value>
            <value>2014</value>
            <value>Jul</value>
            <value></value>
            <value>11</value>
            <value>Epidemiology of Influenza Virus Types and Subtypes in South Africa, 2009-2012(1.)</value>
            <value>1</value>
        </row>
        <row>
            <value>15</value>
            <value>PMID24960272</value>
            <value>6</value>
            <value>6</value>
            <value>2495-504</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>13</value>
            <value>Genetic Diversity in HIV-1 Subtype C LTR from Brazil and Mozambique Generates New Transcription
                Factor-Binding Sites.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>16</value>
            <value>PMID24960249</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>24</value>
            <value>14</value>
            <value>Prevalence and Virologic Consequences of Transmitted HIV-1 Drug Resistance in Uganda.</value>
            <value>0</value>
        </row>
        <row>
            <value>17</value>
            <value>PMID24960032</value>
            <value></value>
            <value></value>
            <value>1-18</value>
            <value>2014</value>
            <value>Jun</value>
            <value>24</value>
            <value>15</value>
            <value>Marital sex among people living with HIV receiving antiretroviral treatment in Northern Thailand.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>18</value>
            <value>PMID24959966</value>
            <value>28</value>
            <value>9</value>
            <value>1375-6</value>
            <value>2014</value>
            <value>Jun</value>
            <value>1</value>
            <value>16</value>
            <value>Isolated hepatitis B surface antigenemia in an HIV-1-positive individual.</value>
            <value>1</value>
        </row>
        <row>
            <value>19</value>
            <value>PMID24959965</value>
            <value>28</value>
            <value>9</value>
            <value>1373-4</value>
            <value>2014</value>
            <value>Jun</value>
            <value>1</value>
            <value>16</value>
            <value>The arrival of untreatable multidrug-resistant HIV-1 in sub-Saharan Africa.</value>
            <value>1</value>
        </row>
        <row>
            <value>20</value>
            <value>PMID24959964</value>
            <value>28</value>
            <value>9</value>
            <value>1365-7</value>
            <value>2014</value>
            <value>Jun</value>
            <value>1</value>
            <value>16</value>
            <value>Acute HIV-1 infection in sub-Saharan Africa: a common occurrence overlooked.</value>
            <value>1</value>
        </row>
        <row>
            <value>21</value>
            <value>PMID24960653</value>
            <value></value>
            <value></value>
            <value>1-8</value>
            <value>2014</value>
            <value>Jun</value>
            <value>5</value>
            <value>17</value>
            <value>Splenectomy improves anaemia but does not reduce iron burden in patients with haemoglobin H Constant
                Spring disease.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>22</value>
            <value>PMID24960628</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>21</value>
            <value>18</value>
            <value>Factors Affecting Outcome Of Related Allogeneic Hematopoietic Cell Transplantation In Patients With
                Fanconi Anemia.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>23</value>
            <value>PMID24960546</value>
            <value></value>
            <value></value>
            <value>jc20141564</value>
            <value>2014</value>
            <value>Jun</value>
            <value>24</value>
            <value>19</value>
            <value>Different Relationships between Body Compositions and Bone Mineral Density According to Gender and
                Age in Korean Populations (KNHANES 2008-2010).
            </value>
            <value>0</value>
        </row>
        <row>
            <value>24</value>
            <value>PMID24960541</value>
            <value></value>
            <value></value>
            <value>jc20134515</value>
            <value>2014</value>
            <value>Jun</value>
            <value>24</value>
            <value>19</value>
            <value>Radiofrequency Ablation, an Effective Modality of Treatment in Tumor-Induced Osteomalacia: A Case
                Series of Three Patients.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>25</value>
            <value>PMID24960451</value>
            <value></value>
            <value></value>
            <value>1-12</value>
            <value>2014</value>
            <value>Jun</value>
            <value>24</value>
            <value>20</value>
            <value>cRGD-conjugated magnetic-fluorescent liposomes for targeted dual-modality imaging of bone metastasis
                from prostate cancer.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>26</value>
            <value>PMID24960414</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>24</value>
            <value>21</value>
            <value>Exposure to Low-Dose (56)Fe-Ion Radiation Induces Long-Term Epigenetic Alterations in Mouse Bone
                Marrow Hematopoietic Progenitor and Stem Cells.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>27</value>
            <value>PMID24960394</value>
            <value>36</value>
            <value>3</value>
            <value>250-3</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>22</value>
            <value>Nephrocalcinosis Associated with Continuous Enamel Hypoplasia and Severe Alveolar Bone Loss: A Case
                Report and Literature Review.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>28</value>
            <value>PMID24960379</value>
            <value>36</value>
            <value>3</value>
            <value>104-6</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>22</value>
            <value>Facial Swelling in a Sickle Cell Patient.</value>
            <value>1</value>
        </row>
        <row>
            <value>29</value>
            <value>PMID24960321</value>
            <value>66</value>
            <value>2</value>
            <value>121-8</value>
            <value>2014</value>
            <value>March-April</value>
            <value></value>
            <value>23</value>
            <value>[Quality of life in patients with bone tumors, a comparison between different treatments.]</value>
            <value>1</value>
        </row>
        <row>
            <value>30</value>
            <value>PMID24960225</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>21</value>
            <value>24</value>
            <value>Recent Advances in Micro/Nanoscale Biomedical Implants.</value>
            <value>0</value>
        </row>
        <row>
            <value>31</value>
            <value>PMID24960613</value>
            <value></value>
            <value></value>
            <value>1-2</value>
            <value>2014</value>
            <value>Jun</value>
            <value>24</value>
            <value>25</value>
            <value>Adenoma malignum of the cervix diagnosed after surgery based on a prediagnosis of ovarian cancer.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>32</value>
            <value>PMID24958986</value>
            <value>35</value>
            <value>1</value>
            <value>43-5</value>
            <value>2014</value>
            <value>Jan</value>
            <value></value>
            <value>26</value>
            <value>Cutaneous metastases presenting as genital ulcer disease.</value>
            <value>1</value>
        </row>
        <row>
            <value>33</value>
            <value>PMID24958910</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>23</value>
            <value>27</value>
            <value>Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent
                vaccine: a nested analysis within the Costa Rica Vaccine Trial.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>34</value>
            <value>PMID24956296</value>
            <value>10</value>
            <value>3</value>
            <value>299-321</value>
            <value>2014</value>
            <value>May</value>
            <value></value>
            <value>28</value>
            <value>Role of imaging in the pretreatment evaluation of common gynecological cancers.</value>
            <value>1</value>
        </row>
        <row>
            <value>35</value>
            <value>PMID24954888</value>
            <value>57</value>
            <value>7</value>
            <value>737-47</value>
            <value>2014</value>
            <value>Jul</value>
            <value></value>
            <value>29</value>
            <value>Cancer incidence in California farm workers, 1988-2010.</value>
            <value>1</value>
        </row>
        <row>
            <value>36</value>
            <value>PMID24954221</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>23</value>
            <value>30</value>
            <value>Immune cells in term and preterm labor.</value>
            <value>0</value>
        </row>
        <row>
            <value>37</value>
            <value>PMID24953027</value>
            <value>83C</value>
            <value></value>
            <value>84-91</value>
            <value>2014</value>
            <value>Jun</value>
            <value>10</value>
            <value>31</value>
            <value>Synthesis and anticancer activity of some novel 5,6-fused hybrids of&#xA0;juglone based
                1,4-naphthoquinones.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>38</value>
            <value>PMID24950889</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>17</value>
            <value>32</value>
            <value>Evaluation of physiological FDG uptake in the skeleton in adults: Is it uniformly distributed?
            </value>
            <value>0</value>
        </row>
        <row>
            <value>39</value>
            <value>PMID24947858</value>
            <value>49 Suppl 2</value>
            <value></value>
            <value>28-32</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>33</value>
            <value>Medical treatment for pyometra in dogs.</value>
            <value>1</value>
        </row>
        <row>
            <value>40</value>
            <value>PMID24947096</value>
            <value>51</value>
            <value>1</value>
            <value>45-53</value>
            <value>2014</value>
            <value>Jan-Mar</value>
            <value></value>
            <value>2</value>
            <value>Spectrum of malignancies in Jaipur region (2004-2008).</value>
            <value>1</value>
        </row>
        <row>
            <value>41</value>
            <value>PMID24957039</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>24</value>
            <value>34</value>
            <value>Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation
                with clinical parameters.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>42</value>
            <value>PMID24955027</value>
            <value>15</value>
            <value>3</value>
            <value>190-202</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>35</value>
            <value>Personalization of targeted therapy in advanced thyroid cancer.</value>
            <value>1</value>
        </row>
        <row>
            <value>43</value>
            <value>PMID24947099</value>
            <value>51</value>
            <value>1</value>
            <value>63-8</value>
            <value>2014</value>
            <value>Jan-Mar</value>
            <value></value>
            <value>2</value>
            <value>Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.</value>
            <value>1</value>
        </row>
        <row>
            <value>44</value>
            <value>PMID24944658</value>
            <value>7</value>
            <value>4</value>
            <value>1001-6</value>
            <value>2014</value>
            <value>Apr</value>
            <value></value>
            <value>36</value>
            <value>A rare case of non-invasive ductal carcinoma of the breast coexisting with follicular lymphoma: A
                case report with a review of the literature.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>45</value>
            <value>PMID24943776</value>
            <value>57</value>
            <value>2</value>
            <value>314-6</value>
            <value>2014</value>
            <value>Apr-Jun</value>
            <value></value>
            <value>37</value>
            <value>Metachronous malignancies in head and neck region: Report of two cases.</value>
            <value>1</value>
        </row>
        <row>
            <value>46</value>
            <value>PMID24937664</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>17</value>
            <value>38</value>
            <value>A putative OTU domain-containing protein 1 deubiquitinating enzyme is differentially expressed in
                thyroid cancer and identifies less-aggressive tumours.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>47</value>
            <value>PMID24936549</value>
            <value></value>
            <value></value>
            <value>1-19</value>
            <value>2014</value>
            <value>Jun</value>
            <value>16</value>
            <value>39</value>
            <value>Thyroid Carcinoma Detected by 18F-Fluorodeoxyglucose Positron Emission Tomography Among Individuals
                Without Prior Evidence of Thyroid Disease: Relevance and Clinicopathological Features.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>48</value>
            <value>PMID24935365</value>
            <value>15</value>
            <value>10</value>
            <value>4169-73</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>40</value>
            <value>Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of lymphoma.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>49</value>
            <value>PMID24932236</value>
            <value>7</value>
            <value>6</value>
            <value>1796-802</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>36</value>
            <value>Thyroid-like follicular carcinoma of the kidney: A report of two cases and literature review.</value>
            <value>1</value>
        </row>
        <row>
            <value>50</value>
            <value>PMID24920192</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>11</value>
            <value>41</value>
            <value>CD117: A novel ancillary marker for papillary thyroid carcinoma in fine-needle aspiration biopsies.
            </value>
            <value>0</value>
        </row>
    </table>
    <table name="article_authors">
        <column>id</column>
        <column>article_id</column>
        <column>position</column>
        <column>last_name</column>
        <column>fore_name</column>
        <column>initials</column>
        <row>
            <value>1</value>
            <value>1</value>
            <value>1</value>
            <value>Kantelhardt</value>
            <value>Eva Johanna</value>
            <value>EJ</value>
        </row>
        <row>
            <value>2</value>
            <value>1</value>
            <value>2</value>
            <value>Moelle</value>
            <value>Ulrike</value>
            <value>U</value>
        </row>
        <row>
            <value>3</value>
            <value>1</value>
            <value>3</value>
            <value>Begoihn</value>
            <value>Matthias</value>
            <value>M</value>
        </row>
        <row>
            <value>4</value>
            <value>1</value>
            <value>4</value>
            <value>Addissie</value>
            <value>Adamu</value>
            <value>A</value>
        </row>
        <row>
            <value>5</value>
            <value>1</value>
            <value>5</value>
            <value>Trocchi</value>
            <value>Pietro</value>
            <value>P</value>
        </row>
        <row>
            <value>6</value>
            <value>1</value>
            <value>6</value>
            <value>Yonas</value>
            <value>Bekuretsion</value>
            <value>B</value>
        </row>
        <row>
            <value>7</value>
            <value>1</value>
            <value>7</value>
            <value>Hezkiel</value>
            <value>Petros</value>
            <value>P</value>
        </row>
        <row>
            <value>8</value>
            <value>1</value>
            <value>8</value>
            <value>Stang</value>
            <value>Andreas</value>
            <value>A</value>
        </row>
        <row>
            <value>9</value>
            <value>1</value>
            <value>9</value>
            <value>Thomssen</value>
            <value>Christoph</value>
            <value>C</value>
        </row>
        <row>
            <value>10</value>
            <value>1</value>
            <value>10</value>
            <value>Vordermark</value>
            <value>Dirk</value>
            <value>D</value>
        </row>
        <row>
            <value>11</value>
            <value>1</value>
            <value>11</value>
            <value>Gemechu</value>
            <value>Tufa</value>
            <value>T</value>
        </row>
        <row>
            <value>12</value>
            <value>1</value>
            <value>12</value>
            <value>Gebrehiwot</value>
            <value>Yirgu</value>
            <value>Y</value>
        </row>
        <row>
            <value>13</value>
            <value>1</value>
            <value>13</value>
            <value>Wondemagegnehu</value>
            <value>Tigeneh</value>
            <value>T</value>
        </row>
        <row>
            <value>14</value>
            <value>1</value>
            <value>14</value>
            <value>Aynalem</value>
            <value>Abreha</value>
            <value>A</value>
        </row>
        <row>
            <value>15</value>
            <value>1</value>
            <value>15</value>
            <value>Mathewos</value>
            <value>Assefa</value>
            <value>A</value>
        </row>
        <row>
            <value>16</value>
            <value>2</value>
            <value>1</value>
            <value>Puri</value>
            <value>S</value>
            <value>S</value>
        </row>
        <row>
            <value>17</value>
            <value>2</value>
            <value>2</value>
            <value>Ashat</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>18</value>
            <value>2</value>
            <value>3</value>
            <value>Pandey</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>19</value>
            <value>2</value>
            <value>4</value>
            <value>Goel</value>
            <value>N K</value>
            <value>NK</value>
        </row>
        <row>
            <value>20</value>
            <value>2</value>
            <value>5</value>
            <value>Singh</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>21</value>
            <value>2</value>
            <value>6</value>
            <value>Kaushal</value>
            <value>V</value>
            <value>V</value>
        </row>
        <row>
            <value>22</value>
            <value>3</value>
            <value>1</value>
            <value>Patton</value>
            <value>Dorothy L</value>
            <value>DL</value>
        </row>
        <row>
            <value>23</value>
            <value>3</value>
            <value>2</value>
            <value>Teng</value>
            <value>Andy</value>
            <value>A</value>
        </row>
        <row>
            <value>24</value>
            <value>3</value>
            <value>3</value>
            <value>Randall</value>
            <value>Arlo</value>
            <value>A</value>
        </row>
        <row>
            <value>25</value>
            <value>3</value>
            <value>4</value>
            <value>Liang</value>
            <value>Xiaowu</value>
            <value>X</value>
        </row>
        <row>
            <value>26</value>
            <value>3</value>
            <value>5</value>
            <value>Felgner</value>
            <value>Philip L</value>
            <value>PL</value>
        </row>
        <row>
            <value>27</value>
            <value>3</value>
            <value>6</value>
            <value>de la Maza</value>
            <value>Luis M</value>
            <value>LM</value>
        </row>
        <row>
            <value>28</value>
            <value>4</value>
            <value>1</value>
            <value>Elit</value>
            <value>Laurie</value>
            <value>L</value>
        </row>
        <row>
            <value>29</value>
            <value>5</value>
            <value>1</value>
            <value>Sankaranarayanan</value>
            <value>Rengaswamy</value>
            <value>R</value>
        </row>
        <row>
            <value>30</value>
            <value>5</value>
            <value>2</value>
            <value>Esmy</value>
            <value>Pulikkottil Okkuru</value>
            <value>PO</value>
        </row>
        <row>
            <value>31</value>
            <value>5</value>
            <value>3</value>
            <value>Rajkumar</value>
            <value>Rajamanickam</value>
            <value>R</value>
        </row>
        <row>
            <value>32</value>
            <value>5</value>
            <value>4</value>
            <value>Muwonge</value>
            <value>Richard</value>
            <value>R</value>
        </row>
        <row>
            <value>33</value>
            <value>5</value>
            <value>5</value>
            <value>Swaminathan</value>
            <value>Rajaraman</value>
            <value>R</value>
        </row>
        <row>
            <value>34</value>
            <value>6</value>
            <value>1</value>
            <value>Suba</value>
            <value>Eric J</value>
            <value>EJ</value>
        </row>
        <row>
            <value>35</value>
            <value>6</value>
            <value>2</value>
            <value>Raab</value>
            <value>Stephen S</value>
            <value>SS</value>
        </row>
        <row>
            <value>36</value>
            <value>7</value>
            <value>1</value>
            <value>Wongsena</value>
            <value>Metee</value>
            <value>M</value>
        </row>
        <row>
            <value>37</value>
            <value>7</value>
            <value>2</value>
            <value>Suebsamran</value>
            <value>Phalakorn</value>
            <value>P</value>
        </row>
        <row>
            <value>38</value>
            <value>7</value>
            <value>3</value>
            <value>Panomket</value>
            <value>Pawana</value>
            <value>P</value>
        </row>
        <row>
            <value>39</value>
            <value>7</value>
            <value>4</value>
            <value>Tirat</value>
            <value>Sutthini</value>
            <value>S</value>
        </row>
        <row>
            <value>40</value>
            <value>7</value>
            <value>5</value>
            <value>Wongsena</value>
            <value>Parichart</value>
            <value>P</value>
        </row>
        <row>
            <value>41</value>
            <value>7</value>
            <value>6</value>
            <value>Wanram</value>
            <value>Surasak</value>
            <value>S</value>
        </row>
        <row>
            <value>42</value>
            <value>8</value>
            <value>1</value>
            <value>Ramogola-Masire</value>
            <value>Doreen</value>
            <value>D</value>
        </row>
        <row>
            <value>43</value>
            <value>8</value>
            <value>2</value>
            <value>Russell</value>
            <value>Anthony H</value>
            <value>AH</value>
        </row>
        <row>
            <value>44</value>
            <value>8</value>
            <value>3</value>
            <value>Dryden-Peterson</value>
            <value>Scott</value>
            <value>S</value>
        </row>
        <row>
            <value>45</value>
            <value>8</value>
            <value>4</value>
            <value>Efstathiou</value>
            <value>Jason A</value>
            <value>JA</value>
        </row>
        <row>
            <value>46</value>
            <value>8</value>
            <value>5</value>
            <value>Kayembe</value>
            <value>Mukendi K A</value>
            <value>MK</value>
        </row>
        <row>
            <value>47</value>
            <value>8</value>
            <value>6</value>
            <value>Wilbur</value>
            <value>David C</value>
            <value>DC</value>
        </row>
        <row>
            <value>48</value>
            <value>9</value>
            <value>1</value>
            <value>Kouros</value>
            <value>Nicole</value>
            <value>N</value>
        </row>
        <row>
            <value>49</value>
            <value>10</value>
            <value>1</value>
            <value>Palmer</value>
            <value>Allyson K</value>
            <value>AK</value>
        </row>
        <row>
            <value>50</value>
            <value>10</value>
            <value>2</value>
            <value>Harris</value>
            <value>Antoneicka L</value>
            <value>AL</value>
        </row>
        <row>
            <value>51</value>
            <value>10</value>
            <value>3</value>
            <value>Jacobson</value>
            <value>Robert M</value>
            <value>RM</value>
        </row>
        <row>
            <value>52</value>
            <value>11</value>
            <value>1</value>
            <value>Okazaki</value>
            <value>Honoka</value>
            <value>H</value>
        </row>
        <row>
            <value>53</value>
            <value>11</value>
            <value>2</value>
            <value>Kaneko</value>
            <value>Chie</value>
            <value>C</value>
        </row>
        <row>
            <value>54</value>
            <value>11</value>
            <value>3</value>
            <value>Hirahara</value>
            <value>Miyuki</value>
            <value>M</value>
        </row>
        <row>
            <value>55</value>
            <value>11</value>
            <value>4</value>
            <value>Watanabe</value>
            <value>Satoru</value>
            <value>S</value>
        </row>
        <row>
            <value>56</value>
            <value>11</value>
            <value>5</value>
            <value>Tochio</value>
            <value>Naoya</value>
            <value>N</value>
        </row>
        <row>
            <value>57</value>
            <value>11</value>
            <value>6</value>
            <value>Kigawa</value>
            <value>Takanori</value>
            <value>T</value>
        </row>
        <row>
            <value>58</value>
            <value>11</value>
            <value>7</value>
            <value>Nishimura</value>
            <value>Chiaki</value>
            <value>C</value>
        </row>
        <row>
            <value>59</value>
            <value>12</value>
            <value>1</value>
            <value>Bitar</value>
            <value>Dounia</value>
            <value>D</value>
        </row>
        <row>
            <value>60</value>
            <value>12</value>
            <value>2</value>
            <value>Lortholary</value>
            <value>Olivier</value>
            <value>O</value>
        </row>
        <row>
            <value>61</value>
            <value>12</value>
            <value>3</value>
            <value>Le Strat</value>
            <value>Yann</value>
            <value>Y</value>
        </row>
        <row>
            <value>62</value>
            <value>12</value>
            <value>4</value>
            <value>Nicolau</value>
            <value>Javier</value>
            <value>J</value>
        </row>
        <row>
            <value>63</value>
            <value>12</value>
            <value>5</value>
            <value>Coignard</value>
            <value>Bruno</value>
            <value>B</value>
        </row>
        <row>
            <value>64</value>
            <value>12</value>
            <value>6</value>
            <value>Tattevin</value>
            <value>Pierre</value>
            <value>P</value>
        </row>
        <row>
            <value>65</value>
            <value>12</value>
            <value>7</value>
            <value>Che</value>
            <value>Didier</value>
            <value>D</value>
        </row>
        <row>
            <value>66</value>
            <value>12</value>
            <value>8</value>
            <value>Dromer</value>
            <value>Fran&#xE7;oise</value>
            <value>F</value>
        </row>
        <row>
            <value>67</value>
            <value>13</value>
            <value>1</value>
            <value>Moyo</value>
            <value>Sabrina</value>
            <value>S</value>
        </row>
        <row>
            <value>68</value>
            <value>13</value>
            <value>2</value>
            <value>Hanevik</value>
            <value>Kurt</value>
            <value>K</value>
        </row>
        <row>
            <value>69</value>
            <value>13</value>
            <value>3</value>
            <value>Blomberg</value>
            <value>Bj&#xF8;rn</value>
            <value>B</value>
        </row>
        <row>
            <value>70</value>
            <value>13</value>
            <value>4</value>
            <value>Kommedal</value>
            <value>Oyvind</value>
            <value>O</value>
        </row>
        <row>
            <value>71</value>
            <value>13</value>
            <value>5</value>
            <value>Vainio</value>
            <value>Kirsti</value>
            <value>K</value>
        </row>
        <row>
            <value>72</value>
            <value>13</value>
            <value>6</value>
            <value>Maselle</value>
            <value>Samuel</value>
            <value>S</value>
        </row>
        <row>
            <value>73</value>
            <value>13</value>
            <value>7</value>
            <value>Langeland</value>
            <value>Nina</value>
            <value>N</value>
        </row>
        <row>
            <value>74</value>
            <value>14</value>
            <value>1</value>
            <value>Cohen</value>
            <value>Adam L</value>
            <value>AL</value>
        </row>
        <row>
            <value>75</value>
            <value>14</value>
            <value>2</value>
            <value>Hellferscee</value>
            <value>Orienka</value>
            <value>O</value>
        </row>
        <row>
            <value>76</value>
            <value>14</value>
            <value>3</value>
            <value>Pretorius</value>
            <value>Marthi</value>
            <value>M</value>
        </row>
        <row>
            <value>77</value>
            <value>14</value>
            <value>4</value>
            <value>Treurnicht</value>
            <value>Florette</value>
            <value>F</value>
        </row>
        <row>
            <value>78</value>
            <value>14</value>
            <value>5</value>
            <value>Walaza</value>
            <value>Sibongile</value>
            <value>S</value>
        </row>
        <row>
            <value>79</value>
            <value>14</value>
            <value>6</value>
            <value>Madhi</value>
            <value>Shabir</value>
            <value>S</value>
        </row>
        <row>
            <value>80</value>
            <value>14</value>
            <value>7</value>
            <value>Groome</value>
            <value>Michelle</value>
            <value>M</value>
        </row>
        <row>
            <value>81</value>
            <value>14</value>
            <value>8</value>
            <value>Dawood</value>
            <value>Halima</value>
            <value>H</value>
        </row>
        <row>
            <value>82</value>
            <value>14</value>
            <value>9</value>
            <value>Variava</value>
            <value>Ebrahim</value>
            <value>E</value>
        </row>
        <row>
            <value>83</value>
            <value>14</value>
            <value>10</value>
            <value>Kahn</value>
            <value>Kathleen</value>
            <value>K</value>
        </row>
        <row>
            <value>84</value>
            <value>14</value>
            <value>11</value>
            <value>Wolter</value>
            <value>Nicole</value>
            <value>N</value>
        </row>
        <row>
            <value>85</value>
            <value>14</value>
            <value>12</value>
            <value>von Gottberg</value>
            <value>Anne</value>
            <value>A</value>
        </row>
        <row>
            <value>86</value>
            <value>14</value>
            <value>13</value>
            <value>Tempia</value>
            <value>Stefano</value>
            <value>S</value>
        </row>
        <row>
            <value>87</value>
            <value>14</value>
            <value>14</value>
            <value>Venter</value>
            <value>Marietjie</value>
            <value>M</value>
        </row>
        <row>
            <value>88</value>
            <value>14</value>
            <value>15</value>
            <value>Cohen</value>
            <value>Cheryl</value>
            <value>C</value>
        </row>
        <row>
            <value>89</value>
            <value>15</value>
            <value>1</value>
            <value>Boullosa</value>
            <value>Jos&#xE9;</value>
            <value>J</value>
        </row>
        <row>
            <value>90</value>
            <value>15</value>
            <value>2</value>
            <value>Bachu</value>
            <value>Mahesh</value>
            <value>M</value>
        </row>
        <row>
            <value>91</value>
            <value>15</value>
            <value>3</value>
            <value>Bila</value>
            <value>Dulce</value>
            <value>D</value>
        </row>
        <row>
            <value>92</value>
            <value>15</value>
            <value>4</value>
            <value>Ranga</value>
            <value>Udaykumar</value>
            <value>U</value>
        </row>
        <row>
            <value>93</value>
            <value>15</value>
            <value>5</value>
            <value>S&#xFC;ffert</value>
            <value>Theodoro</value>
            <value>T</value>
        </row>
        <row>
            <value>94</value>
            <value>15</value>
            <value>6</value>
            <value>Sasazawa</value>
            <value>Tomoko</value>
            <value>T</value>
        </row>
        <row>
            <value>95</value>
            <value>15</value>
            <value>7</value>
            <value>Tanuri</value>
            <value>Amilcar</value>
            <value>A</value>
        </row>
        <row>
            <value>96</value>
            <value>16</value>
            <value>1</value>
            <value>Lee</value>
            <value>Guinevere Q</value>
            <value>GQ</value>
        </row>
        <row>
            <value>97</value>
            <value>16</value>
            <value>2</value>
            <value>Bangsberg</value>
            <value>David R</value>
            <value>DR</value>
        </row>
        <row>
            <value>98</value>
            <value>16</value>
            <value>3</value>
            <value>Muzoora</value>
            <value>Conrad</value>
            <value>C</value>
        </row>
        <row>
            <value>99</value>
            <value>16</value>
            <value>4</value>
            <value>Boum</value>
            <value>Yap</value>
            <value>Y</value>
        </row>
        <row>
            <value>100</value>
            <value>16</value>
            <value>5</value>
            <value>Oyugi</value>
            <value>Jessica H</value>
            <value>JH</value>
        </row>
        <row>
            <value>101</value>
            <value>16</value>
            <value>6</value>
            <value>Emenyonu</value>
            <value>Nneka</value>
            <value>N</value>
        </row>
        <row>
            <value>102</value>
            <value>16</value>
            <value>7</value>
            <value>Bennett</value>
            <value>John</value>
            <value>J</value>
        </row>
        <row>
            <value>103</value>
            <value>16</value>
            <value>8</value>
            <value>Hunt</value>
            <value>P W</value>
            <value>PW</value>
        </row>
        <row>
            <value>104</value>
            <value>16</value>
            <value>9</value>
            <value>Knapp</value>
            <value>David</value>
            <value>D</value>
        </row>
        <row>
            <value>105</value>
            <value>16</value>
            <value>10</value>
            <value>Brumme</value>
            <value>Chanson J</value>
            <value>CJ</value>
        </row>
        <row>
            <value>106</value>
            <value>16</value>
            <value>11</value>
            <value>Harrigan</value>
            <value>P Richard</value>
            <value>PR</value>
        </row>
        <row>
            <value>107</value>
            <value>16</value>
            <value>12</value>
            <value>Martin</value>
            <value>Jeff</value>
            <value>J</value>
        </row>
        <row>
            <value>108</value>
            <value>17</value>
            <value>1</value>
            <value>Le Coeur</value>
            <value>Sophie</value>
            <value>S</value>
        </row>
        <row>
            <value>109</value>
            <value>17</value>
            <value>2</value>
            <value>Bozon</value>
            <value>Michel</value>
            <value>M</value>
        </row>
        <row>
            <value>110</value>
            <value>17</value>
            <value>3</value>
            <value>Leli&#xE8;vre</value>
            <value>Eva</value>
            <value>E</value>
        </row>
        <row>
            <value>111</value>
            <value>17</value>
            <value>4</value>
            <value>Sirijitraporn</value>
            <value>Preecha</value>
            <value>P</value>
        </row>
        <row>
            <value>112</value>
            <value>17</value>
            <value>5</value>
            <value>Pipustanawong</value>
            <value>Narongdate</value>
            <value>N</value>
        </row>
        <row>
            <value>113</value>
            <value>17</value>
            <value>6</value>
            <value>Cowatcharagul</value>
            <value>Worawut</value>
            <value>W</value>
        </row>
        <row>
            <value>114</value>
            <value>17</value>
            <value>7</value>
            <value>Pattanapornpun</value>
            <value>Nopporn</value>
            <value>N</value>
        </row>
        <row>
            <value>115</value>
            <value>18</value>
            <value>1</value>
            <value>Smith</value>
            <value>Sarah</value>
            <value>S</value>
        </row>
        <row>
            <value>116</value>
            <value>18</value>
            <value>2</value>
            <value>Mounzer</value>
            <value>Karam</value>
            <value>K</value>
        </row>
        <row>
            <value>117</value>
            <value>19</value>
            <value>1</value>
            <value>Magambo</value>
            <value>Brian</value>
            <value>B</value>
        </row>
        <row>
            <value>118</value>
            <value>19</value>
            <value>2</value>
            <value>Nazziwa</value>
            <value>Jamirah</value>
            <value>J</value>
        </row>
        <row>
            <value>119</value>
            <value>19</value>
            <value>3</value>
            <value>Bbosa</value>
            <value>Nicholas</value>
            <value>N</value>
        </row>
        <row>
            <value>120</value>
            <value>19</value>
            <value>4</value>
            <value>Gupta</value>
            <value>Ravindra K</value>
            <value>RK</value>
        </row>
        <row>
            <value>121</value>
            <value>19</value>
            <value>5</value>
            <value>Kaleebu</value>
            <value>Pontiano</value>
            <value>P</value>
        </row>
        <row>
            <value>122</value>
            <value>19</value>
            <value>6</value>
            <value>Parry</value>
            <value>Chris M</value>
            <value>CM</value>
        </row>
        <row>
            <value>123</value>
            <value>20</value>
            <value>1</value>
            <value>Powers</value>
            <value>Kimberly A</value>
            <value>KA</value>
        </row>
        <row>
            <value>124</value>
            <value>20</value>
            <value>2</value>
            <value>Cohen</value>
            <value>Myron S</value>
            <value>MS</value>
        </row>
        <row>
            <value>125</value>
            <value>21</value>
            <value>1</value>
            <value>Zhou</value>
            <value>Ya-Li</value>
            <value>YL</value>
        </row>
        <row>
            <value>126</value>
            <value>21</value>
            <value>2</value>
            <value>Zhang</value>
            <value>Xin-Hua</value>
            <value>XH</value>
        </row>
        <row>
            <value>127</value>
            <value>21</value>
            <value>3</value>
            <value>Liu</value>
            <value>Tie-Niu</value>
            <value>TN</value>
        </row>
        <row>
            <value>128</value>
            <value>21</value>
            <value>4</value>
            <value>Wang</value>
            <value>Li</value>
            <value>L</value>
        </row>
        <row>
            <value>129</value>
            <value>21</value>
            <value>5</value>
            <value>Yin</value>
            <value>Xiao-Lin</value>
            <value>XL</value>
        </row>
        <row>
            <value>130</value>
            <value>22</value>
            <value>1</value>
            <value>Ayas</value>
            <value>Mouhab</value>
            <value>M</value>
        </row>
        <row>
            <value>131</value>
            <value>22</value>
            <value>2</value>
            <value>Siddiqui</value>
            <value>Khawar</value>
            <value>K</value>
        </row>
        <row>
            <value>132</value>
            <value>22</value>
            <value>3</value>
            <value>Al-Jefri</value>
            <value>Abdullah</value>
            <value>A</value>
        </row>
        <row>
            <value>133</value>
            <value>22</value>
            <value>4</value>
            <value>El-Solh</value>
            <value>Hassan</value>
            <value>H</value>
        </row>
        <row>
            <value>134</value>
            <value>22</value>
            <value>5</value>
            <value>Al-Ahmari</value>
            <value>Ali</value>
            <value>A</value>
        </row>
        <row>
            <value>135</value>
            <value>22</value>
            <value>6</value>
            <value>Khairy</value>
            <value>Ashraf</value>
            <value>A</value>
        </row>
        <row>
            <value>136</value>
            <value>22</value>
            <value>7</value>
            <value>Markiz</value>
            <value>Samer</value>
            <value>S</value>
        </row>
        <row>
            <value>137</value>
            <value>22</value>
            <value>8</value>
            <value>Shahin</value>
            <value>Hasan</value>
            <value>H</value>
        </row>
        <row>
            <value>138</value>
            <value>22</value>
            <value>9</value>
            <value>Al-Musa</value>
            <value>Abdulrahman</value>
            <value>A</value>
        </row>
        <row>
            <value>139</value>
            <value>22</value>
            <value>10</value>
            <value>Al-Seraihy</value>
            <value>Amal</value>
            <value>A</value>
        </row>
        <row>
            <value>140</value>
            <value>23</value>
            <value>1</value>
            <value>Hee Ahn</value>
            <value>Seong</value>
            <value>S</value>
        </row>
        <row>
            <value>141</value>
            <value>23</value>
            <value>2</value>
            <value>Hun Lee</value>
            <value>Seung</value>
            <value>S</value>
        </row>
        <row>
            <value>142</value>
            <value>23</value>
            <value>3</value>
            <value>Kim</value>
            <value>Hyeonmok</value>
            <value>H</value>
        </row>
        <row>
            <value>143</value>
            <value>23</value>
            <value>4</value>
            <value>Kim</value>
            <value>Beom-Jun</value>
            <value>BJ</value>
        </row>
        <row>
            <value>144</value>
            <value>23</value>
            <value>5</value>
            <value>Koh</value>
            <value>Jung-Min</value>
            <value>JM</value>
        </row>
        <row>
            <value>145</value>
            <value>24</value>
            <value>1</value>
            <value>Jadhav</value>
            <value>Swati</value>
            <value>S</value>
        </row>
        <row>
            <value>146</value>
            <value>24</value>
            <value>2</value>
            <value>Kasaliwal</value>
            <value>Rajeev</value>
            <value>R</value>
        </row>
        <row>
            <value>147</value>
            <value>24</value>
            <value>3</value>
            <value>Shetty</value>
            <value>Nitin S</value>
            <value>NS</value>
        </row>
        <row>
            <value>148</value>
            <value>24</value>
            <value>4</value>
            <value>Kulkarni</value>
            <value>Suyash</value>
            <value>S</value>
        </row>
        <row>
            <value>149</value>
            <value>24</value>
            <value>5</value>
            <value>Rathod</value>
            <value>Krantikumar</value>
            <value>K</value>
        </row>
        <row>
            <value>150</value>
            <value>24</value>
            <value>6</value>
            <value>Popat</value>
            <value>Bhavesh</value>
            <value>B</value>
        </row>
        <row>
            <value>151</value>
            <value>24</value>
            <value>7</value>
            <value>Kakade</value>
            <value>Harshal</value>
            <value>H</value>
        </row>
        <row>
            <value>152</value>
            <value>24</value>
            <value>8</value>
            <value>Bukan</value>
            <value>Amol</value>
            <value>A</value>
        </row>
        <row>
            <value>153</value>
            <value>24</value>
            <value>9</value>
            <value>Khare</value>
            <value>Shruti</value>
            <value>S</value>
        </row>
        <row>
            <value>154</value>
            <value>24</value>
            <value>10</value>
            <value>Budyal</value>
            <value>Sweta</value>
            <value>S</value>
        </row>
        <row>
            <value>155</value>
            <value>24</value>
            <value>11</value>
            <value>Jagtap</value>
            <value>Varsha S</value>
            <value>VS</value>
        </row>
        <row>
            <value>156</value>
            <value>24</value>
            <value>12</value>
            <value>Lila</value>
            <value>Anurag R</value>
            <value>AR</value>
        </row>
        <row>
            <value>157</value>
            <value>24</value>
            <value>13</value>
            <value>Bandgar</value>
            <value>Tushar</value>
            <value>T</value>
        </row>
        <row>
            <value>158</value>
            <value>24</value>
            <value>14</value>
            <value>Shah</value>
            <value>Nalini S</value>
            <value>NS</value>
        </row>
        <row>
            <value>159</value>
            <value>25</value>
            <value>1</value>
            <value>Wang</value>
            <value>Fangfang</value>
            <value>F</value>
        </row>
        <row>
            <value>160</value>
            <value>25</value>
            <value>2</value>
            <value>Chen</value>
            <value>Zhongping</value>
            <value>Z</value>
        </row>
        <row>
            <value>161</value>
            <value>25</value>
            <value>3</value>
            <value>Zhu</value>
            <value>Li</value>
            <value>L</value>
        </row>
        <row>
            <value>162</value>
            <value>26</value>
            <value>1</value>
            <value>Miousse</value>
            <value>Isabelle R</value>
            <value>IR</value>
        </row>
        <row>
            <value>163</value>
            <value>26</value>
            <value>2</value>
            <value>Shao</value>
            <value>Lijian</value>
            <value>L</value>
        </row>
        <row>
            <value>164</value>
            <value>26</value>
            <value>3</value>
            <value>Chang</value>
            <value>Jianhui</value>
            <value>J</value>
        </row>
        <row>
            <value>165</value>
            <value>26</value>
            <value>4</value>
            <value>Feng</value>
            <value>Wei</value>
            <value>W</value>
        </row>
        <row>
            <value>166</value>
            <value>26</value>
            <value>5</value>
            <value>Wang</value>
            <value>Yingying</value>
            <value>Y</value>
        </row>
        <row>
            <value>167</value>
            <value>26</value>
            <value>6</value>
            <value>Allen</value>
            <value>Anti&#xF1;o R</value>
            <value>AR</value>
        </row>
        <row>
            <value>168</value>
            <value>26</value>
            <value>7</value>
            <value>Turner</value>
            <value>Jennifer</value>
            <value>J</value>
        </row>
        <row>
            <value>169</value>
            <value>26</value>
            <value>8</value>
            <value>Stewart</value>
            <value>Blair</value>
            <value>B</value>
        </row>
        <row>
            <value>170</value>
            <value>26</value>
            <value>9</value>
            <value>Raber</value>
            <value>Jacob</value>
            <value>J</value>
        </row>
        <row>
            <value>171</value>
            <value>26</value>
            <value>10</value>
            <value>Zhou</value>
            <value>Daohong</value>
            <value>D</value>
        </row>
        <row>
            <value>172</value>
            <value>26</value>
            <value>11</value>
            <value>Koturbash</value>
            <value>Igor</value>
            <value>I</value>
        </row>
        <row>
            <value>173</value>
            <value>27</value>
            <value>1</value>
            <value>Ashkenazi</value>
            <value>Malka</value>
            <value>M</value>
        </row>
        <row>
            <value>174</value>
            <value>27</value>
            <value>2</value>
            <value>Rafe</value>
            <value>Zvi</value>
            <value>Z</value>
        </row>
        <row>
            <value>175</value>
            <value>27</value>
            <value>3</value>
            <value>Sarnat</value>
            <value>Haim</value>
            <value>H</value>
        </row>
        <row>
            <value>176</value>
            <value>27</value>
            <value>4</value>
            <value>Levin</value>
            <value>Liran</value>
            <value>L</value>
        </row>
        <row>
            <value>177</value>
            <value>28</value>
            <value>1</value>
            <value>DeBlieux</value>
            <value>Tyler K</value>
            <value>TK</value>
        </row>
        <row>
            <value>178</value>
            <value>28</value>
            <value>2</value>
            <value>Jackson</value>
            <value>Neal</value>
            <value>N</value>
        </row>
        <row>
            <value>179</value>
            <value>28</value>
            <value>3</value>
            <value>Jeyakumar</value>
            <value>Anita</value>
            <value>A</value>
        </row>
        <row>
            <value>180</value>
            <value>28</value>
            <value>4</value>
            <value>Townsend</value>
            <value>Janice A</value>
            <value>JA</value>
        </row>
        <row>
            <value>181</value>
            <value>28</value>
            <value>5</value>
            <value>Naik</value>
            <value>Bijal V</value>
            <value>BV</value>
        </row>
        <row>
            <value>182</value>
            <value>29</value>
            <value>1</value>
            <value>Gonz&#xE1;lez-Rodr&#xED;guez</value>
            <value>Eva</value>
            <value>E</value>
        </row>
        <row>
            <value>183</value>
            <value>29</value>
            <value>2</value>
            <value>Riveros</value>
            <value>Ang&#xE9;lica</value>
            <value>A</value>
        </row>
        <row>
            <value>184</value>
            <value>29</value>
            <value>3</value>
            <value>Benjet</value>
            <value>Corina</value>
            <value>C</value>
        </row>
        <row>
            <value>185</value>
            <value>29</value>
            <value>4</value>
            <value>Gonz&#xE1;lez-Forteza</value>
            <value>Catalina</value>
            <value>C</value>
        </row>
        <row>
            <value>186</value>
            <value>29</value>
            <value>5</value>
            <value>Le&#xF3;n-Hern&#xE1;ndez</value>
            <value>Sa&#xFA;l Ren&#xE1;n</value>
            <value>SR</value>
        </row>
        <row>
            <value>187</value>
            <value>29</value>
            <value>6</value>
            <value>Rico-Mart&#xED;nez</value>
            <value>Genaro</value>
            <value>G</value>
        </row>
        <row>
            <value>188</value>
            <value>30</value>
            <value>1</value>
            <value>Arsiwala</value>
            <value>Ammar</value>
            <value>A</value>
        </row>
        <row>
            <value>189</value>
            <value>30</value>
            <value>2</value>
            <value>Desai</value>
            <value>Preshita</value>
            <value>P</value>
        </row>
        <row>
            <value>190</value>
            <value>30</value>
            <value>3</value>
            <value>Patravale</value>
            <value>Vandana</value>
            <value>V</value>
        </row>
        <row>
            <value>191</value>
            <value>31</value>
            <value>1</value>
            <value>Solmaz</value>
            <value>U</value>
            <value>U</value>
        </row>
        <row>
            <value>192</value>
            <value>31</value>
            <value>2</value>
            <value>Dereli</value>
            <value>L</value>
            <value>L</value>
        </row>
        <row>
            <value>193</value>
            <value>31</value>
            <value>3</value>
            <value>Mat</value>
            <value>E</value>
            <value>E</value>
        </row>
        <row>
            <value>194</value>
            <value>31</value>
            <value>4</value>
            <value>Peker</value>
            <value>N</value>
            <value>N</value>
        </row>
        <row>
            <value>195</value>
            <value>31</value>
            <value>5</value>
            <value>Adiyeke</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>196</value>
            <value>31</value>
            <value>6</value>
            <value>K&#xFC;c&#xFC;k</value>
            <value>U</value>
            <value>U</value>
        </row>
        <row>
            <value>197</value>
            <value>32</value>
            <value>1</value>
            <value>Vasuki</value>
            <value>S</value>
            <value>S</value>
        </row>
        <row>
            <value>198</value>
            <value>32</value>
            <value>2</value>
            <value>Durgalakshmi</value>
            <value>J</value>
            <value>J</value>
        </row>
        <row>
            <value>199</value>
            <value>32</value>
            <value>3</value>
            <value>Latha</value>
            <value>J</value>
            <value>J</value>
        </row>
        <row>
            <value>200</value>
            <value>33</value>
            <value>1</value>
            <value>Kuhs</value>
            <value>Krystle A Lang</value>
            <value>KA</value>
        </row>
        <row>
            <value>201</value>
            <value>33</value>
            <value>2</value>
            <value>Gonzalez</value>
            <value>Paula</value>
            <value>P</value>
        </row>
        <row>
            <value>202</value>
            <value>33</value>
            <value>3</value>
            <value>Rodriguez</value>
            <value>Ana Cecilia</value>
            <value>AC</value>
        </row>
        <row>
            <value>203</value>
            <value>33</value>
            <value>4</value>
            <value>van Doorn</value>
            <value>Leen-Jan</value>
            <value>LJ</value>
        </row>
        <row>
            <value>204</value>
            <value>33</value>
            <value>5</value>
            <value>Schiffman</value>
            <value>Mark</value>
            <value>M</value>
        </row>
        <row>
            <value>205</value>
            <value>33</value>
            <value>6</value>
            <value>Struijk</value>
            <value>Linda</value>
            <value>L</value>
        </row>
        <row>
            <value>206</value>
            <value>33</value>
            <value>7</value>
            <value>Chen</value>
            <value>Sabrina</value>
            <value>S</value>
        </row>
        <row>
            <value>207</value>
            <value>33</value>
            <value>8</value>
            <value>Quint</value>
            <value>Wim</value>
            <value>W</value>
        </row>
        <row>
            <value>208</value>
            <value>33</value>
            <value>9</value>
            <value>Lowy</value>
            <value>Douglas R</value>
            <value>DR</value>
        </row>
        <row>
            <value>209</value>
            <value>33</value>
            <value>10</value>
            <value>Porras</value>
            <value>Carolina</value>
            <value>C</value>
        </row>
        <row>
            <value>210</value>
            <value>33</value>
            <value>11</value>
            <value>DelVecchio</value>
            <value>Corey</value>
            <value>C</value>
        </row>
        <row>
            <value>211</value>
            <value>33</value>
            <value>12</value>
            <value>Jimenez</value>
            <value>Silvia</value>
            <value>S</value>
        </row>
        <row>
            <value>212</value>
            <value>33</value>
            <value>13</value>
            <value>Safaeian</value>
            <value>Mahboobeh</value>
            <value>M</value>
        </row>
        <row>
            <value>213</value>
            <value>33</value>
            <value>14</value>
            <value>Schiller</value>
            <value>John</value>
            <value>J</value>
        </row>
        <row>
            <value>214</value>
            <value>33</value>
            <value>15</value>
            <value>Wacholder</value>
            <value>Sholom</value>
            <value>S</value>
        </row>
        <row>
            <value>215</value>
            <value>33</value>
            <value>16</value>
            <value>Herrero</value>
            <value>Rolando</value>
            <value>R</value>
        </row>
        <row>
            <value>216</value>
            <value>33</value>
            <value>17</value>
            <value>Hildesheim</value>
            <value>Allan</value>
            <value>A</value>
        </row>
        <row>
            <value>217</value>
            <value>33</value>
            <value>18</value>
            <value>Kreimer</value>
            <value>Aim&#xE9;e R</value>
            <value>AR</value>
        </row>
        <row>
            <value>218</value>
            <value>33</value>
            <value>19</value>
            <value></value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>219</value>
            <value>34</value>
            <value>1</value>
            <value>Micc&#xF2;</value>
            <value>Maura</value>
            <value>M</value>
        </row>
        <row>
            <value>220</value>
            <value>34</value>
            <value>2</value>
            <value>Sala</value>
            <value>Evis</value>
            <value>E</value>
        </row>
        <row>
            <value>221</value>
            <value>34</value>
            <value>3</value>
            <value>Lakhman</value>
            <value>Yulia</value>
            <value>Y</value>
        </row>
        <row>
            <value>222</value>
            <value>34</value>
            <value>4</value>
            <value>Hricak</value>
            <value>Hedvig</value>
            <value>H</value>
        </row>
        <row>
            <value>223</value>
            <value>34</value>
            <value>5</value>
            <value>Vargas</value>
            <value>Hebert Alberto</value>
            <value>HA</value>
        </row>
        <row>
            <value>224</value>
            <value>35</value>
            <value>1</value>
            <value>Mills</value>
            <value>Paul K</value>
            <value>PK</value>
        </row>
        <row>
            <value>225</value>
            <value>35</value>
            <value>2</value>
            <value>Shah</value>
            <value>Purvi</value>
            <value>P</value>
        </row>
        <row>
            <value>226</value>
            <value>36</value>
            <value>1</value>
            <value>Gomez-Lopez</value>
            <value>Nardhy</value>
            <value>N</value>
        </row>
        <row>
            <value>227</value>
            <value>36</value>
            <value>2</value>
            <value>StLouis</value>
            <value>Derek</value>
            <value>D</value>
        </row>
        <row>
            <value>228</value>
            <value>36</value>
            <value>3</value>
            <value>Lehr</value>
            <value>Marcus A</value>
            <value>MA</value>
        </row>
        <row>
            <value>229</value>
            <value>36</value>
            <value>4</value>
            <value>Sanchez-Rodriguez</value>
            <value>Elly N</value>
            <value>EN</value>
        </row>
        <row>
            <value>230</value>
            <value>36</value>
            <value>5</value>
            <value>Arenas-Hernandez</value>
            <value>Marcia</value>
            <value>M</value>
        </row>
        <row>
            <value>231</value>
            <value>37</value>
            <value>1</value>
            <value>Mallavadhani</value>
            <value>Uppuluri Venkata</value>
            <value>UV</value>
        </row>
        <row>
            <value>232</value>
            <value>37</value>
            <value>2</value>
            <value>Prasad</value>
            <value>Chakka Vara</value>
            <value>CV</value>
        </row>
        <row>
            <value>233</value>
            <value>37</value>
            <value>3</value>
            <value>Shrivastava</value>
            <value>Shweta</value>
            <value>S</value>
        </row>
        <row>
            <value>234</value>
            <value>37</value>
            <value>4</value>
            <value>Naidu</value>
            <value>V G M</value>
            <value>VG</value>
        </row>
        <row>
            <value>235</value>
            <value>38</value>
            <value>1</value>
            <value>Aras</value>
            <value>Mustafa</value>
            <value>M</value>
        </row>
        <row>
            <value>236</value>
            <value>38</value>
            <value>2</value>
            <value>Dede</value>
            <value>Fuat</value>
            <value>F</value>
        </row>
        <row>
            <value>237</value>
            <value>38</value>
            <value>3</value>
            <value>Ones</value>
            <value>Tunc</value>
            <value>T</value>
        </row>
        <row>
            <value>238</value>
            <value>38</value>
            <value>4</value>
            <value>Inan&#x131;r</value>
            <value>Sabahat</value>
            <value>S</value>
        </row>
        <row>
            <value>239</value>
            <value>38</value>
            <value>5</value>
            <value>Erd&#x131;l</value>
            <value>Tanju Yusuf</value>
            <value>TY</value>
        </row>
        <row>
            <value>240</value>
            <value>38</value>
            <value>6</value>
            <value>Turoglu</value>
            <value>Halil Turgut</value>
            <value>HT</value>
        </row>
        <row>
            <value>241</value>
            <value>39</value>
            <value>1</value>
            <value>Fieni</value>
            <value>F</value>
            <value>F</value>
        </row>
        <row>
            <value>242</value>
            <value>39</value>
            <value>2</value>
            <value>Topie</value>
            <value>E</value>
            <value>E</value>
        </row>
        <row>
            <value>243</value>
            <value>39</value>
            <value>3</value>
            <value>Gogny</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>244</value>
            <value>40</value>
            <value>1</value>
            <value>Sharma</value>
            <value>R G</value>
            <value>RG</value>
        </row>
        <row>
            <value>245</value>
            <value>40</value>
            <value>2</value>
            <value>Kapoor</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>246</value>
            <value>40</value>
            <value>3</value>
            <value>Bang</value>
            <value>B A</value>
            <value>BA</value>
        </row>
        <row>
            <value>247</value>
            <value>40</value>
            <value>4</value>
            <value>Gurjar</value>
            <value>K</value>
            <value>K</value>
        </row>
        <row>
            <value>248</value>
            <value>41</value>
            <value>1</value>
            <value>Rao</value>
            <value>P Jagan Mohan</value>
            <value>PJ</value>
        </row>
        <row>
            <value>249</value>
            <value>41</value>
            <value>2</value>
            <value>Vardhini</value>
            <value>N V</value>
            <value>NV</value>
        </row>
        <row>
            <value>250</value>
            <value>41</value>
            <value>3</value>
            <value>Parvathi</value>
            <value>M V S</value>
            <value>MV</value>
        </row>
        <row>
            <value>251</value>
            <value>41</value>
            <value>4</value>
            <value>Murthy</value>
            <value>P Balakrishna</value>
            <value>PB</value>
        </row>
        <row>
            <value>252</value>
            <value>41</value>
            <value>5</value>
            <value>Sudhakar</value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>253</value>
            <value>42</value>
            <value>1</value>
            <value>Fallahi</value>
            <value>Poupak</value>
            <value>P</value>
        </row>
        <row>
            <value>254</value>
            <value>42</value>
            <value>2</value>
            <value>Ferrari</value>
            <value>Silvia Martina</value>
            <value>SM</value>
        </row>
        <row>
            <value>255</value>
            <value>42</value>
            <value>3</value>
            <value>Mazzi</value>
            <value>Valeria</value>
            <value>V</value>
        </row>
        <row>
            <value>256</value>
            <value>42</value>
            <value>4</value>
            <value>Vita</value>
            <value>Roberto</value>
            <value>R</value>
        </row>
        <row>
            <value>257</value>
            <value>42</value>
            <value>5</value>
            <value>Benvenga</value>
            <value>Salvatore</value>
            <value>S</value>
        </row>
        <row>
            <value>258</value>
            <value>42</value>
            <value>6</value>
            <value>Antonelli</value>
            <value>Alessandro</value>
            <value>A</value>
        </row>
        <row>
            <value>259</value>
            <value>43</value>
            <value>1</value>
            <value>Atik</value>
            <value>E</value>
            <value>E</value>
        </row>
        <row>
            <value>260</value>
            <value>43</value>
            <value>2</value>
            <value>Guray</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>261</value>
            <value>43</value>
            <value>3</value>
            <value>Gunesacar</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>262</value>
            <value>43</value>
            <value>4</value>
            <value>Ozgur</value>
            <value>T</value>
            <value>T</value>
        </row>
        <row>
            <value>263</value>
            <value>43</value>
            <value>5</value>
            <value>Canda</value>
            <value>T</value>
            <value>T</value>
        </row>
        <row>
            <value>264</value>
            <value>44</value>
            <value>1</value>
            <value>Tamaoki</value>
            <value>Mikako</value>
            <value>M</value>
        </row>
        <row>
            <value>265</value>
            <value>44</value>
            <value>2</value>
            <value>Nio</value>
            <value>Yoshinori</value>
            <value>Y</value>
        </row>
        <row>
            <value>266</value>
            <value>44</value>
            <value>3</value>
            <value>Tsuboi</value>
            <value>Kazuhiko</value>
            <value>K</value>
        </row>
        <row>
            <value>267</value>
            <value>44</value>
            <value>4</value>
            <value>Nio</value>
            <value>Marika</value>
            <value>M</value>
        </row>
        <row>
            <value>268</value>
            <value>44</value>
            <value>5</value>
            <value>Tamaoki</value>
            <value>Masashi</value>
            <value>M</value>
        </row>
        <row>
            <value>269</value>
            <value>44</value>
            <value>6</value>
            <value>Maruyama</value>
            <value>Riruke</value>
            <value>R</value>
        </row>
        <row>
            <value>270</value>
            <value>45</value>
            <value>1</value>
            <value>Yalavarthi</value>
            <value>Sushma</value>
            <value>S</value>
        </row>
        <row>
            <value>271</value>
            <value>45</value>
            <value>2</value>
            <value>Pamu</value>
            <value>Pramod Kumar</value>
            <value>PK</value>
        </row>
        <row>
            <value>272</value>
            <value>45</value>
            <value>3</value>
            <value>Thoondla</value>
            <value>Mallesh</value>
            <value>M</value>
        </row>
        <row>
            <value>273</value>
            <value>45</value>
            <value>4</value>
            <value>Gupta</value>
            <value>Saloni</value>
            <value>S</value>
        </row>
        <row>
            <value>274</value>
            <value>46</value>
            <value>1</value>
            <value>Carneiro</value>
            <value>A P</value>
            <value>AP</value>
        </row>
        <row>
            <value>275</value>
            <value>46</value>
            <value>2</value>
            <value>Reis</value>
            <value>C F</value>
            <value>CF</value>
        </row>
        <row>
            <value>276</value>
            <value>46</value>
            <value>3</value>
            <value>Morari</value>
            <value>E C</value>
            <value>EC</value>
        </row>
        <row>
            <value>277</value>
            <value>46</value>
            <value>4</value>
            <value>Maia</value>
            <value>Y C P</value>
            <value>YC</value>
        </row>
        <row>
            <value>278</value>
            <value>46</value>
            <value>5</value>
            <value>Nascimento</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>279</value>
            <value>46</value>
            <value>6</value>
            <value>Bonatto</value>
            <value>J M C</value>
            <value>JM</value>
        </row>
        <row>
            <value>280</value>
            <value>46</value>
            <value>7</value>
            <value>de Souza</value>
            <value>M A</value>
            <value>MA</value>
        </row>
        <row>
            <value>281</value>
            <value>46</value>
            <value>8</value>
            <value>Goulart</value>
            <value>L R</value>
            <value>LR</value>
        </row>
        <row>
            <value>282</value>
            <value>46</value>
            <value>9</value>
            <value>Ward</value>
            <value>L S</value>
            <value>LS</value>
        </row>
        <row>
            <value>283</value>
            <value>47</value>
            <value>1</value>
            <value>Marques</value>
            <value>Pedro</value>
            <value>P</value>
        </row>
        <row>
            <value>284</value>
            <value>47</value>
            <value>2</value>
            <value>Rat&#xE3;o</value>
            <value>Pedro</value>
            <value>P</value>
        </row>
        <row>
            <value>285</value>
            <value>47</value>
            <value>3</value>
            <value>Salgado</value>
            <value>Luc&#xED;lia</value>
            <value>L</value>
        </row>
        <row>
            <value>286</value>
            <value>47</value>
            <value>4</value>
            <value>Bugalho</value>
            <value>Maria Jo&#xE3;o</value>
            <value>MJ</value>
        </row>
        <row>
            <value>287</value>
            <value>48</value>
            <value>1</value>
            <value>Senturk</value>
            <value>Aysegul</value>
            <value>A</value>
        </row>
        <row>
            <value>288</value>
            <value>48</value>
            <value>2</value>
            <value>Babaoglu</value>
            <value>Elif</value>
            <value>E</value>
        </row>
        <row>
            <value>289</value>
            <value>48</value>
            <value>3</value>
            <value>Kilic</value>
            <value>Hatice</value>
            <value>H</value>
        </row>
        <row>
            <value>290</value>
            <value>48</value>
            <value>4</value>
            <value>Hezer</value>
            <value>Habibe</value>
            <value>H</value>
        </row>
        <row>
            <value>291</value>
            <value>48</value>
            <value>5</value>
            <value>Dogan</value>
            <value>Hayriye Tatli</value>
            <value>HT</value>
        </row>
        <row>
            <value>292</value>
            <value>48</value>
            <value>6</value>
            <value>Hasanoglu</value>
            <value>Hatice Canan</value>
            <value>HC</value>
        </row>
        <row>
            <value>293</value>
            <value>48</value>
            <value>7</value>
            <value>Bilaceroglu</value>
            <value>Semra</value>
            <value>S</value>
        </row>
        <row>
            <value>294</value>
            <value>49</value>
            <value>1</value>
            <value>Lin</value>
            <value>Yun-Zhi</value>
            <value>YZ</value>
        </row>
        <row>
            <value>295</value>
            <value>49</value>
            <value>2</value>
            <value>Wei</value>
            <value>Yong</value>
            <value>Y</value>
        </row>
        <row>
            <value>296</value>
            <value>49</value>
            <value>3</value>
            <value>Xu</value>
            <value>Ning</value>
            <value>N</value>
        </row>
        <row>
            <value>297</value>
            <value>49</value>
            <value>4</value>
            <value>Li</value>
            <value>Xiao-Dong</value>
            <value>XD</value>
        </row>
        <row>
            <value>298</value>
            <value>49</value>
            <value>5</value>
            <value>Xue</value>
            <value>Xue-Yi</value>
            <value>XY</value>
        </row>
        <row>
            <value>299</value>
            <value>49</value>
            <value>6</value>
            <value>Zheng</value>
            <value>Qing-Shui</value>
            <value>QS</value>
        </row>
        <row>
            <value>300</value>
            <value>49</value>
            <value>7</value>
            <value>Jiang</value>
            <value>Tao</value>
            <value>T</value>
        </row>
        <row>
            <value>301</value>
            <value>49</value>
            <value>8</value>
            <value>Huang</value>
            <value>Jin-Bei</value>
            <value>JB</value>
        </row>
        <row>
            <value>302</value>
            <value>50</value>
            <value>1</value>
            <value>Pusztaszeri</value>
            <value>Marc P</value>
            <value>MP</value>
        </row>
        <row>
            <value>303</value>
            <value>50</value>
            <value>2</value>
            <value>Sadow</value>
            <value>Peter M</value>
            <value>PM</value>
        </row>
        <row>
            <value>304</value>
            <value>50</value>
            <value>3</value>
            <value>Faquin</value>
            <value>William C</value>
            <value>WC</value>
        </row>
    </table>
    <table name="article_abstract_paras">
        <column>id</column>
        <column>article_id</column>
        <column>position</column>
        <column>heading</column>
        <column>nlm_category</column>
        <column>para</column>
        <row>
            <value>1</value>
            <value>1</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Almost 500,000 women are newly diagnosed with cervical cancer (CC) every year, the majority from
                developing countries. There is little information on the survival of these patients. Our primary
                objective was to evaluate consecutive CC patients presenting over 4 years at the only radiotherapy
                center in Ethiopia.METHODS: All patients with CC from September 2008 to September 2012 who received
                radiotherapy and/or surgery were included (without brachytherapy). Vital status was obtained through
                telephone contact or patient cards.RESULTS: Of 2,300 CC patients, 1,059 patients with standardized
                treatment were included. At the end of the study, 249 patients had died; surviving patients had a median
                follow-up of 16.5 months; the 10% and 90% percentiles were 3.0 and 32.7 months, respectively. Mean age
                was 49 years (21-91 years). The majority of patients presented with International Federation of
                Gynecology and Obstetrics stage IIb-IIIa (46.7%). Because of progression during the waiting time (median
                3.8 months), this proportion declined to 19.3% at the beginning of radiotherapy. The 1- and 2-year
                overall survival probabilities were 90.4% and 73.6%. If assuming a worst-case scenario (i.e., if all
                patients not available for follow-up after 6 months had died), the 2-year survival probability would be
                45.4%.CONCLUSION: This study gives a thorough 4-year overview of treated patients with CC in Ethiopia.
                Given the limited treatment availability, a relatively high proportion of patients survived 2 years.
                More prevention and early detection at all levels of the health care system are needed. Increasing the
                capacity for external-beam radiation as well as options for brachytherapy would facilitate treatment
                with curative intention.
            </value>
        </row>
        <row>
            <value>2</value>
            <value>2</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Aim: To determine the socio-demographic characteristics of cancer patients. Materials and Methods:
                Review of the Cancer registry, and patient interview. Information on socio-demographic profile, medical
                history, family history and previous treatment, if any, was retrieved from the patient. If the patient
                couldn't be contacted then information was taken from pathology/radiotherapy or medical records
                department. Results: A total of 684 patients participated in the study. More than 40% of males and 53.7%
                of females were illiterate, P &lt; 0.05. The majority (33.5%) of participants were of low socioeconomic
                status. The most frequently reported cancer (ca) in males it was ca lung (40.9) and ca oesophagus (9.8).
                In females most common cancer were ca breast (23.9) followed by ca cervix (11.7).
            </value>
        </row>
        <row>
            <value>3</value>
            <value>3</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>The cervix and/or fallopian tubes of pigtailed macaques were experimentally infected with Chlamydia
                trachomatis. Their sera were collected at varying time points and screened for identification of
                immunodominant antigens using a whole-genome protein microarray. The effect of doxycycline treatment on
                the antibody response generated in these macaques was also investigated. Twenty-five female macaques
                were infected with C. trachomatis serovars D or E in the cervix and/or fallopian tubes. Bloods were
                collected at baseline and at various intervals after challenge. Serum samples were tested for antibodies
                using a C. trachomatis serovar D protein microarray. Twenty chlamydial antigens reacted with sera from
                at least 68% (17/25) of the macaques. In addition to some well-known chlamydial antigens, nine different
                proteins, not previously recognized as immunodominant, including four hypothetical proteins (CT005,
                CT066, CT360 and CT578), were identified. Monkeys infected in the fallopian tubes developed a more
                robust antibody response than animals inoculated in the cervix. Treatment with doxycycline significantly
                decreased Chlamydia-specific antibody levels. In summary, using protein microarray serum samples from
                experimentally infected pigtailed macaques were screened for immunodominant chlamydial antigens. These
                antigens can now be tested in animal models for their ability to protect and as markers of disease
                progression.
            </value>
        </row>
        <row>
            <value>4</value>
            <value>3</value>
            <value>2</value>
            <value>Biological significance</value>
            <value>Unassigned</value>
            <value>This is the first time that Chlamydia trachomatis immunodominant antigens have been identified in
                pigtailed macaques following a uterine cervix or a fallopian tubes infection. These immunodominant
                antigens can now be used to vaccinate non-human primates and determine their ability to protect against
                a C. trachomatis genital infection. Proteins that are protective can subsequently be tested in humans.
                Amongst the immunodominant antigens some were predominantly recognized by sera from macaques inoculated
                in the fallopian tubes rather than in the cervix and therefore, may be markers for upper genital tract
                pathology. In addition, treatment with doxycycline following infection significantly decreased
                Chlamydia-specific antibody levels. This information can be used to evaluate the efficacy of antibiotic
                treatment and potentially susceptibility to reinfection.
            </value>
        </row>
        <row>
            <value>5</value>
            <value>4</value>
            <value>1</value>
            <value>Objectives</value>
            <value>Objective</value>
            <value>(1) To understand whether women who are older when diagnosed with cervical cancer have a poorer
                survival compared to those younger, and if so, to determine the relative importance of patient, tumor
                and treatment factors. (2) To review whether older women are candidates for aggressive curative
                treatment for their cervical cancer and the age related effectiveness and toxicity.
            </value>
        </row>
        <row>
            <value>6</value>
            <value>4</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>A review of the published English literature from 1990 to 2014 using search terms related to cervical
                cancer and older age was conducted.
            </value>
        </row>
        <row>
            <value>7</value>
            <value>4</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>A number of confounders may influence whether advanced age impacts survival such as patient
                comorbidities, stage, histology, grade, no or incomplete treatment, less radical surgery, palliative
                rather than curative treatment, lack of adjuvant radiation after surgery, lower rates of chemotherapy
                and others. When older women are treated as aggressively as their younger counterparts, survival is the
                same; however, especially where radiation or chemotherapy is used, toxicities may occur at the same or
                slightly higher rate.
            </value>
        </row>
        <row>
            <value>8</value>
            <value>4</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>The more recent population based studies have larger sample sizes and minimize the biases seen in
                single center studies. They have also corrected for confounders giving a more accurate answer concerning
                the outcomes of older women treated for cervical cancer. Performance status (or "frailty") and not
                chronologic age should define the optimal treatment strategy for older women with cervical cancer.
                Treatment related toxicities can be managed with treatment breaks or dose reductions. For those who
                receive curative treatment, the outcomes appear similar regardless of age.
            </value>
        </row>
        <row>
            <value>9</value>
            <value>7</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Cervical cancer (CXCA) caused by persistent infections by high-risk human papillomavirus (HR-HPV) can
                lead to multi-step carcinogenesis. The best management strategy and significant prognosis for cervical
                cancer patients remain unclear.
            </value>
        </row>
        <row>
            <value>10</value>
            <value>7</value>
            <value>2</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>To investigate the associations of the two most common HR-HPVs with clinical outcomes of progression
                and recurrence status as well as prognosis outcomes of patients.
            </value>
        </row>
        <row>
            <value>11</value>
            <value>7</value>
            <value>3</value>
            <value>Material and method</value>
            <value>Methods</value>
            <value>An analytical cross-sectional study of patients registered at Ubon Ratchathani Cancer Hospital was
                conducted from 2007 to 2010. Clinical data, histopathological features, and clinical outcomes of
                progression and recurrence status were recorded. HPV type-specific E6/E7 nested multiplex polymerase
                chain reaction (NMPCR) was performed to identify HR-HPV16 and 18 using extracted deoxyribonucleic acid
                (DNA) from embedded paraffin. Clinical findings and HPV genotypes were analyzed using Fisher's exact
                test. Association studies of crucial factors and HR-HPV genotypes were performed using logistic
                regression analysis (odds ratio [OR]) and 95% confidence interval [CI]). A p-value of less than 0.05 was
                considered statistically significant.
            </value>
        </row>
        <row>
            <value>12</value>
            <value>7</value>
            <value>4</value>
            <value>Results</value>
            <value>Results</value>
            <value>The study found single HPV16 infection in 57.3%, single HPV18 in 17.3%, mixed HR-HPV16/18 in 13.1%,
                and non-HPV16, 18, or 16/18 in 12.3%. The findings showed significant association among their genotypes
                and histopathological types and grading (p &lt; 0.0001 and p = 0.014). Clinical outcomes of progression
                and recurrence status with increased severity of clinical staging were associated significantly (p =
                0.001 and p = 0.002). HPV18 type-specific was shown as a poor prognostic type with its relevance to the
                severity of disease higher than that of HPV16.
            </value>
        </row>
        <row>
            <value>13</value>
            <value>7</value>
            <value>5</value>
            <value>Conclusion and discussion</value>
            <value>Conclusions</value>
            <value>HPV16 and 18 remain the major type-specifics especially in relation to invasive CXCA, requiring
                further therapeutic vaccination study and proper prognosis. HR-HPV type-specific is very important
                during cervical carcinogenesis but other crucial contributing factors for prognostic outcomes should be
                further elucidated.
            </value>
        </row>
        <row>
            <value>14</value>
            <value>10</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Each year 610,000 cases of anogenital and oropharyngeal cancers caused by human papillomavirus (HPV)
                occur worldwide. HPV vaccination represents a promising opportunity to prevent cancer on a global scale.
                The vaccine's story dates back to discoveries in chickens at the beginning of the 20th century with
                evidence that a cell-free filtrate could transmit the propensity to grow cancers. Later, studies with
                similarly derived filtrates from mammalian tumors showed that hosts could develop immunity to subsequent
                exposures. Epidemiologic studies linked cervical cancer to members of a family of viruses that cause
                papillomatosis and common warts. This led to work with DNA hybridization demonstrating a causal
                relationship. The formation of virus-like particles from viral capsid proteins led to the development of
                models for safe and effective vaccines. While much work remains with the acceptance of universal
                vaccination, the HPV vaccines Gardasil and Cervarix thus represent a century of successful translational
                research.
            </value>
        </row>
        <row>
            <value>15</value>
            <value>11</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>N-terminal domain of HIV-1 p24 capsid protein is a globular fold composed of seven helices and two
                &#x3B2;-strands with a flexible structure including the &#x3B1;4-5 loop and both N- and C-terminal ends.
                However, the protein shows a high tendency (48%) for an intrinsically disordered structure based on the
                PONDR VL-XT prediction from the primary sequence. To assess the possibility of marginally stabilized
                structure under physiological conditions, the N-terminal domain of p24 was destabilized by the addition
                of an artificial flexible tag to either N- or C-terminal ends, and it was analyzed using T1, T2,
                hetero-nuclear NOE, and amide-proton exchange experiments. When the C-terminal tag (12 residues) was
                attached, the regions of the &#x3B1;3-4 loop and helix 6 as well as the &#x3B1;4-5 loop attained the
                flexible structures. Furthermore, in the protein containing the N-terminal tag (27 residues), helix 4 in
                addition to above-mentioned area including &#x3B1;3-4 and &#x3B1;4-5 loops as well as helix 6 exhibited
                highly disordered structures. Thus, the long-range effects of the existence of tag sequence was observed
                in the stepwise manner of the appearance of disordered structures (step 1: &#x3B1;4-5 loop, step 2:
                &#x3B1;3-4 loop and helix 6, and step 3: helix 4). Furthermore, the disordered regions in tagged
                proteins were consistent with the PONDR VL-XT disordered prediction. The dynamic structure located in
                the middle part (&#x3B1;3-4 loop to helix 6) of the protein shown in this study may be related to the
                assembly of the viral particle.
            </value>
        </row>
        <row>
            <value>16</value>
            <value>12</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>To determine the epidemiology and trends of invasive fungal infections (IFIs) in France, we analyzed
                incidence, risk factors, and in-hospital death rates related to the most frequent IFIs registered in the
                national hospital discharge database during 2001-2010. The identified 35,876 IFI cases included
                candidemia (43.4%), Pneumocystis jirovecii pneumonia (26.1%), invasive aspergillosis (IA, 23.9%),
                cryptococcosis (5.2%), and mucormycosis (1.5%). The overall incidence was 5.9/100,000 cases/year and the
                mortality rate was 27.6%; both increased over the period (+1.5%, +2.9%/year, respectively). Incidences
                substantially increased for candidemia, IA, and mucormycosis. Pneumocystis jirovecii pneumonia incidence
                decreased among AIDS patients (-14.3%/year) but increased in non-HIV-infected patients (+13.3%/year).
                Candidemia and IA incidence was increased among patients with hematologic malignancies (&gt;+4%/year)
                and those with chronic renal failure (&gt;+10%/year). In-hospital deaths substantially increased in some
                groups, e.g., in those with hematologic malignancies. IFIs occur among a broad spectrum of
                non-HIV-infected patients and should be a major public health priority.
            </value>
        </row>
        <row>
            <value>17</value>
            <value>13</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>This study investigated and reports norovirus diarrhoea, genetic diversity and associated clinical
                symptoms, HIV status and seasonality in a paediatric population of Tanzania. Stool specimens and
                demographic/clinical information, were prospectively collected from 705 hospitalised children with
                diarrhoea (cases) and 561 children without diarrhoea (controls) between 2010-2011. Norovirus detection
                was done by real-time RT-PCR. Genotype was determined using Gel-based and real time RT-PCR methods and
                sequencing targeting the polymerase and the capsid region respectively. Norovirus was detected in 14.3%,
                181/1266 children. The prevalence of norovirus was significantly higher in cases (18.3%, 129/705) than
                in controls, (9.2%, 52/561), P&lt;0.05. Except for one child who had double infection with GI and GII
                all 129 cases had GII. Among controls, 23.1% had GI and 76.9% had GII. Norovirus GII.4 was significantly
                more prevalent in cases 87.9% than in controls 56.5%. Other genotypes detected in both cases and
                controls were GII.21, GII.16 and GII.g. The highest numbers of norovirus were detected in April 2011.
                The number of norovirus detected was significantly higher during the first than second year of life
                (109/540, 20.2% vs. 20/165, 12.1%). The prevalence of norovirus in HIV-positive and negative children
                was (21.2%, 7/33) and (10.3%, 40/390, P=0.05) respectively, regardless of diarrhoea symptoms. No
                significant difference in gender, parent's level of education or nutritional status with norovirus
                infection was observed within cases or controls. This study confirms the significant role of norovirus
                infection, especially GII.4 in diarrhoeic children who need hospitalisation and adds knowledge on
                norovirus epidemiology in the African region.
            </value>
        </row>
        <row>
            <value>18</value>
            <value>14</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>To determine clinical and epidemiologic differences between influenza caused by different virus types
                and subtypes, we identified patients and tested specimens. Patients were children and adults
                hospitalized with confirmed influenza and severe acute respiratory illness (SARI) identified through
                active, prospective, hospital-based surveillance from 2009-2012 in South Africa. Respiratory specimens
                were tested, typed, and subtyped for influenza virus by PCR. Of 16,005 SARI patients tested, 1,239 (8%)
                were positive for influenza virus. Patient age and co-infections varied according to virus type and
                subtype, but disease severity did not. Case-patients with influenza B were more likely than patients
                with influenza A to be HIV infected. A higher proportion of case-patients infected during the first wave
                of the 2009 influenza pandemic were 5-24 years of age (19%) than were patients infected during the
                second wave (9%). Although clinical differences exist, treatment recommendations do not differ according
                to subtype; prevention through vaccination is recommended.
            </value>
        </row>
        <row>
            <value>19</value>
            <value>15</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>The HIV-1 subtype C has been substituting the subtype B population in southern Brazil. This
                phenomenon has been previously described in other countries, suggesting that subtype C may possess
                greater fitness than other subtypes. The HIV-1 long-terminal repeat (LTR) is an important regulatory
                region critical for the viral life cycle. Sequence insertions immediately upstream of the viral enhancer
                are known as the most frequent naturally occurring length polimorphisms (MFNLP). Previous reports
                demonstrated that the MFNLP could lead to the duplication of transcription factor binding sites (TFBS)
                enhancing the activity of the HIV-1 subtype C LTR. Here, we amplified and sequenced the LTR obtained
                from proviral DNA samples collected from patients infected with subtype C from the Southern Region of
                Brazil (na&#xEF;ve or treatment failure) and Mozambique (only na&#xEF;ve). We confirm the presence of
                different types of insertions in the LTR sequences of both the countries leading to the creation of
                additional TFBS. In the Brazilian clinical samples, the frequency of the sequence insertion was
                significantly higher in subjects experiencing treatment failure than in antiretroviral na&#xEF;ve
                patients.
            </value>
        </row>
        <row>
            <value>20</value>
            <value>16</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Background: Few reports have examined the impact of HIV-1 transmitted drug resistance (TDR) in
                resource-limited settings where there are fewer regimen-choices and limited pre-/post-therapy
                resistance-testing. In this study, we examined TDR prevalence in Kampala and Mbarara, Uganda and
                assessed its virologic consequences after antiretroviral-therapy initiation. Methods: We sequenced the
                HIV-1 protease/reverse transcriptase from n=81 and n=491 treatment-na&#xEF;ve participants of the Uganda
                AIDS Rural Treatment Outcomes (UARTO) pilot study in Kampala (AMU 2002-2004) and main cohort in Mbarara
                (MBA 2005-2010). TDR-associated mutations were defined by the WHO 2009 surveillance mutation list.
                Post-treatment viral load data were available for both populations. Results: Overall TDR prevalence was
                7% (Kampala) and 3% (Mbarara) with no significant time trend. There was a slight but statistically
                nonsignificant trend that the presence of TDR was associated with worse treatment outcome: Virologic
                suppression (&lt;=400 copies/mL within six-months post-therapy-initiation) was achieved in 87% and 96%
                of participants with wildtype viruses, versus 67% and 83% of participants with TDR (AMU, MBA p=0.2 and
                0.1); time-to-suppression (log-rank p=0.3 and p=0.05). Overall, 85% and 96% of study participants
                achieved suppression regardless of TDR status. Surprisingly, among the TDR cases, approximately half
                still achieved suppression; the presence of pre-therapy K103N while on nevirapine and fewer active drugs
                in first-regimen were most often observed with failures. Conclusion: The majority of patients benefited
                from the local HIV-care system even without resistance-monitoring. Overall TDR prevalence was relatively
                low and its presence did not always imply treatment failure.
            </value>
        </row>
        <row>
            <value>21</value>
            <value>17</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Before the advent of effective antiretroviral treatment (ART), the sexuality of people living with
                HIV was mostly discussed in terms of risk. To assess the extent to which ART allows people living with
                HIV to regain a regular sexual life, we surveyed all HIV-infected people treated in four hospitals in
                Northern Thailand and a control group from the general population matched by sex, age and residence.
                Data included socio-demographic and health characteristics, frequency of sexual intercourse in the last
                month and condom use. Our findings indicate that people living with HIV less often live in steady
                partnership (50% of the HIV-infected people versus 79% of the controls). After adjusting for factors
                known to influence sexuality, their probability of being sexually active was estimated to be about half
                that of the controls. When sexually active, men had a reduced sexual activity compared to controls (2.8
                intercourse in the last month versus 4.0), while levels of reported sexual activity were similar among
                women (2.2 versus 2.8, respectively). Consistent condom use was high among people living with HIV (66%
                for women and 70% for men).
            </value>
        </row>
        <row>
            <value>22</value>
            <value>21</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Splenectomy is reported to increase the haemoglobin level in patients with haemoglobin H Constant
                Spring (HbH CS) disease; however, its impact on iron burden and the underlying mechanism remains
                unclear.
            </value>
        </row>
        <row>
            <value>23</value>
            <value>21</value>
            <value>2</value>
            <value>Materials and methods</value>
            <value>Methods</value>
            <value>From March through to May 2013, a total of 50 adults with HbH CS disease (25 cases splenectomised and
                25 cases non-splenectomised) were enrolled. The patients' general conditions, history of blood
                transfusion and iron chelator treatment were investigated. Levels of haemoglobin, nucleated red blood
                cell counts, and serum ferritin were measured. The percentage of apoptotic erythroid precursor cells in
                bone marrow, an index representing ineffective erythropoiesis, was determined in some cases.
            </value>
        </row>
        <row>
            <value>24</value>
            <value>21</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>There were no significant differences in age, blood transfusion volume, and use of iron chelator
                drugs between the splenectomised group and the non-splenectomised group. Significantly higher
                haemoglobin levels, serum ferritin levels and nucleated red blood cell counts as well as a higher
                percentage of apoptotic erythroid progenitor cells were detected in the splenectomised group. Regression
                analysis revealed that age and nucleated red blood cell counts were independent risk factors affecting
                the serum ferritin level.
            </value>
        </row>
        <row>
            <value>25</value>
            <value>21</value>
            <value>4</value>
            <value>Discussion</value>
            <value>Conclusions</value>
            <value>Despite improving the haemoglobin level, splenectomy is associated with greater iron burden in HbH CS
                disease. A high nucleated red blood cell count is predictive of the risk of severe iron overload.
            </value>
        </row>
        <row>
            <value>26</value>
            <value>22</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi Anemia
                (FA), and it is generally accepted that these patients should receive low intensity conditioning due to
                the underlying DNA repair defect in their cells. Outcomes of recipients of matched related HCT have
                generally been favorable, but only few studies have scrutinized the factors that may impact on the
                eventual outcome of these patients. This retrospective analysis of 94 pediatric patients with FA who
                underwent related HCT at KFSHRC was carried out to attempt to identify factors that may impact on
                outcome. Results showed overall survival probabilities (OS) of 92.5%, 89%, and 86% at 1, 5, and 10
                years, respectively. In univariate analysis, use of higher dose cyclophosphamide (CY; 60mg/kg)
                conditioning was associated with a better 10-year OS than lower dose CY (20mg/kg) conditioning (91 % vs.
                82 %, respectively; P =0.035), and use of radiation-containing regimens was associated with a
                significantly lower 10-year OS than non-radiation regimens (76 % vs. 91 %, respectively; P =0.005). Of
                all the 4 regimens used in this study, the fludarabine based regimen was associated with the highest
                survival (95.2%; P= 0.034). The use of the higher CY dose (60mg/kg) was associated with a significantly
                increased incidence of hemorrhagic cystitis (20% vs. 5.6% respectively; P =0.049). Three patients (3%)
                developed squamous cell carcinoma (2 oropharyngeal and one genitourinary), at 9.5, 5.5, 14 years post
                HCT; 2 of them had radiation containing conditioning. In conclusion, our data suggest that while using a
                higher dose CY (60 mg/kg) conditioning regimen may be associated with better survival, it is also
                associated with a significantly increased risk of hemorrhagic cystitis. The addition of fludarabine to
                the low dose CY (20 mg/kg) is associated with the best survival. On the other hand, radiation-containing
                regimens are associated with significantly lower survival.
            </value>
        </row>
        <row>
            <value>27</value>
            <value>23</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Context: Fat and muscle are linked to bone metabolism. Objective: To investigate the association of
                fat mass (FM) and lean mass (LM) with bone mineral density (BMD) according to gender and age Design and
                Setting: A population-based, cross-sectional study from Korea National Health and Nutrition Examination
                Surveys Participants: 15,036 Koreans (6,692 men and 8,344 women) aged 10-95 years Main outcome measures:
                BMD and body compositions were measured using a dual-energy X-ray absorptiometry. BMD was determined at
                the femoral neck, total hip, and lumbar spine. Body compositions included total FM (TFM), percentage FM
                (PFM), truncal FM (TrFM), total LM (TLM), and appendicular skeletal muscle mass/weight (ASM/Wt).
                Results: We categorized each man and woman into one of three age groups, based on changes in age-related
                BMD and the hormonal status. In all gender and age groups, TFM, PFM and TrFM associated inversely with
                BMD (P&lt;0.001-0.034), while TLM and ASM/Wt associated positively (P&lt;0.001-0.037) after adjusting
                for confounders. The negative contribution of FM (P&lt;0.001-0.034), and the positive contribution of LM
                (P&lt;0.001-0.035) on BMD were significantly stronger in men than in women. The associations were
                strongest in men of growing age (P=0.003-0.040). When we subdivided the subjects into four groups based
                on median values of PFM and TLM, FM had a greater effect than LM on BMD in men (P&lt;0.001-0.006).
                Conclusion: These results demonstrate that the effects of FM and LM on BMD may be based on gender and
                age.
            </value>
        </row>
        <row>
            <value>28</value>
            <value>24</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Context: Tumor-induced osteomalacia is curable if the tumors can be totally excised. However, when
                the tumors are present in locations that make surgery disproportionately risky, the need for less
                invasive strategies like radiofrequency ablation (RFA) is realized. Patients and Methods: We describe
                three patients with suspected tumor-induced osteomalacia who were treated in our department between 2006
                and 2013 with tumors in surgically difficult locations and were subjected to single or multiple sessions
                of RFA. The response was documented in terms of symptomatic improvement, phosphorus normalization, and
                follow-up (99m)Technitium-labelled hydrazinonicotinyl-Tyr3-octreotide ((99m)Tc HYNIC TOC) scan. Results:
                Two of the three individuals, patient A (with a 1.5 &#xD7; 1.2-cm lesion in the head of the right femur)
                and patient B (with a 1.3 &#xD7; 1.2-cm lesion on the endosteal surface of the shaft of the left femur),
                achieved complete remission with single sessions of RFA. Three months after the procedure, (99m)Tc HYNIC
                TOC scans revealed the absence of uptake at the previous sites, corroborating with the clinical
                improvement and phosphorus normalization. Patient C had a large 5.6 &#xD7; 6.5-cm complex lesion in the
                lower end of the left femur with irregular margins, loculations, and bone grafts placed in previous
                surgery. He failed to achieve remission after multiple sessions of RFA due to the complex nature of the
                lesion, although the tumor burden was reduced significantly as documented on serial (99m)Tc HYNIC TOC
                scans. Conclusions: Although surgery remains the treatment of choice, RFA could be an effective, less
                invasive, and safe modality of treatment in judiciously selected patients.
            </value>
        </row>
        <row>
            <value>29</value>
            <value>25</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Abstract We reported the development of multifunctional liposomes as a dual-modality probe to
                facilitate targeted magnetic resonance and fluorescent imaging of bone metastasis from advanced cancer.
                Multifunctional liposomes consisted of liposomes as a carrier, hydrophobic CdSe QDs in phospholipid
                bilayer, hydrophilic iron oxide nanoparticles in interior vesicle, lipid-PEG derivative on the surface
                and cRGDyk peptide conjugated to distal ends of lipid-PEG derivative. Excellent stability, effective
                detection signal, low toxicity, high resistance to phagocytosis by macrophages and good specificity to
                tumor of multifunctional liposomes were confirmed by in vitro characterization. The in vivo results
                demonstrated that multifunctional liposomes accumulated mainly in tumor and liver, indicating that
                targeted dual-modality imaging was achieved, and the results from two kinds of modalities were
                consistent and complementary. These findings provide a helpful strategy for detection of bone metastases
                in a more effective manner for initiation of appropriate therapy.
            </value>
        </row>
        <row>
            <value>30</value>
            <value>26</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>There is an increasing need to better understand the long-term health effects of high-linear energy
                transfer (LET) radiation due to exposure during space missions, as well as its increasing use in
                clinical treatments. Previous studies have indicated that exposure to (56)Fe heavy ions increases the
                incidence of acute myeloid leukemia (AML) in mice but the underlying molecular mechanisms remain
                elusive. Epigenetic alterations play a role in radiation-induced genomic instability and the initiation
                and progression of AML. In this study, we assessed the effects of low-dose (56)Fe-ion irradiation on
                epigenetic alterations in bone marrow mononuclear cells (BM-MNCs) and hematopoietic progenitor and stem
                cells (HPSCs). Exposure to (56)Fe ions (600 MeV, 0.1, 0.2 and 0.4 Gy) resulted in significant epigenetic
                alterations involving methylation of DNA, the DNA methylation machinery and expression of repetitive
                elements. Four weeks after irradiation, these changes were primarily confined to HPSCs and were
                exhibited as dose-dependent hypermethylation of LINE1 and SINE B1 repetitive elements [4.2-fold increase
                in LINE1 (P &lt; 0.001) and 7.6-fold increase in SINE B1 (P &lt; 0.01) after exposure to 0.4 Gy; n = 5].
                Epigenetic alterations were persistent and detectable for at least 22 weeks after exposure, when
                significant loss of global DNA hypomethylation (1.9-fold, P &lt; 0.05), decreased expression of Dnmt1
                (1.9-fold, P &lt; 0.01), and increased expression of LINE1 and SINE B1 repetitive elements (2.8-fold, P
                &lt; 0.001 for LINE1 and 1.9-fold, P &lt; 0.05 for SINE B1; n = 5) were observed after exposure to 0.4
                Gy. In contrast, exposure to (56)Fe ions did not result in accumulation of increased production of
                reactive oxygen species (ROS) and DNA damage, exhibited as DNA strand breaks. Furthermore, no
                significant alterations in cellular senescence and apoptosis were detected in HPSCs after exposure to
                (56)Fe-ion radiation. These findings suggest that epigenetic reprogramming is possibly involved in the
                development of radiation-induced genomic instability and thus, may have a causative role in the
                development of AML.
            </value>
        </row>
        <row>
            <value>31</value>
            <value>27</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Enamel-renal syndrome (ERS) is a rare manifestation of nephrocalcinosis that has been associated with
                generalized enamel hypoplasia. The purpose of this paper was to describe, for the first time, the
                association of enamel-renal syndrome with severe localized periodontal bone loss. A 13-year-old boy
                presented with: generalized hypoplastic enamel; intrapulpal calcifications; retention of primary teeth;
                delayed eruption of permanent teeth; enlarged dental-follicles; misshaped roots of permanent teeth;
                gingival overgrowth; severe localized alveolar bone loss; and severe malocclusion. His parents were
                first cousins, suggesting autosomal recessive inheritance. Further studies are necessary to clarify
                whether the etiology of the oral disturbances relates to the genetic defect in the dental tissue or to
                the continuous metabolic distress associated with renal dysfunction. Nevertheless, since
                nephrocalcinosis is often asymptomatic, dentists should refer children with generalized enamel
                hypoplasia or/and multiple intrapulpal calcifications to nephrologists.
            </value>
        </row>
        <row>
            <value>32</value>
            <value>28</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Sickle cell disease (SCD) is characterized as a chronic hemolytic anemia with vaso-occlusive crises
                that result in multisystem organ damage. Bone marrow is one of the more common sites of these crises,
                presumably due to marrow hypercellularity that impairs blood flow- leading to regional hypoxia and
                subsequent infarction. Infarcts of facial bones are considered an uncommon complication of SCD. When
                infarcts occur in facial bones, the mandible and orbital bones are the most commonly affected. Overall,
                the clinical presentation of facial bone infarctions may mimic an infectious process, such as
                cellulitis, an abscess, or, more commonly, osteomyelitis. The purpose of this paper was to present the
                case of a patient with a confluence of symptoms in the face as a result of her sickle cell disease.
            </value>
        </row>
        <row>
            <value>33</value>
            <value>29</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>INTRODUCTION. Previously, amputation was the only treatment option for patients with malignant bone
                tumors. Due to technological, medical and surgical advances, the number of survivors and years of
                survival has been increasing, and thus, the interest in evaluating the impact of this disease on quality
                of life. OBJECTIVE. To evaluate the health related quality of life reported by patients with bone tumors
                undergoing different treatments (no surgery/amputation/salvage). MATERIAL AND METHODS. Patients (n = 85)
                with bone tumors over the age of 18, both sexes, from the Instituto Nacional de Rehabilitaci&#xF3;n of
                Mexico City were included, divided into three groups according to type of treatment. The study design
                was cross-sectional, descriptive of a nonrandom sample. Quality of life was assessed with the Inventory
                of Quality of Life and Health (InCaViSa). Data were analyzed using descriptive statistics, comparisons
                between patients with different treatments were evaluated with multivariate analysis of covariance and
                Sidak post hoc tests. RESULTS. Statistically significant differences were detected in six of the twelve
                areas of quality of life that are assessed by the scale: physical functioning, isolation, body
                perception, treatment attitude leisure time and daily life. Health related quality of life in the study
                group is best for those patients who received amputation compared with the other treatments, while
                patients limb salvage procedures are those with greater impairment.
            </value>
        </row>
        <row>
            <value>34</value>
            <value>30</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>The medical device industry is growing at a very fast pace and has recorded great research activity
                over the past decade. The interdisciplinary nature of this field has made it possible for researchers to
                incorporate principles from various allied areas like pharmaceutics, bioengineering biotechnology,
                chemistry, electronics, biophysics etc. to develop superior medical solutions, offering better prospects
                to the patient. Moreover, micro and nanotechnology has made it possible to positively affect at the
                sub-micron scales, the cellular processes initiated upon implantation. Literature is rife with findings
                on various implants and this review comprehensively summarizes the recent advances in micro/nano scale
                implantable medical devices - particularly cardiovascular implants, neural implants, orthopedic and
                dental implants and other miscellaneous implants. Over the years, medical implants have metamorphosed
                from mere support providing devices to smart interventions participating positively in the healing
                process. We have highlighted the current research in each area emphasizing on the value addition
                provided by micro/nano scale features, its course through the past and the future perspectives focusing
                on the unmet needs.
            </value>
        </row>
        <row>
            <value>35</value>
            <value>32</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Cutaneous metastasis from an internal organ malignancy is rare and as, the presenting sign of
                malignancy is an uncommon phenomenon. Their presence, signals a poor prognosis. We report a case of
                50-year-old female who was referred to sexually transmitted diseases - out patient department, with
                complaints of multiple genital ulcers to rule out sexually transmitted infections. After thorough
                evaluation, she was found to be a case of carcinoma cervix with metastatic squamous cell carcinomatous
                deposits on external genitalia. This case was unique because of relatively asymptomatic nature of
                internal malignancy and atypical presentation of carcinoma cervix as cutaneous metastasis.
            </value>
        </row>
        <row>
            <value>36</value>
            <value>33</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>&#x2003;Vaccine efficacy (VE) against vulvar human papillomavirus (HPV) infection has not been
                reported and data regarding its epidemiology are sparse.
            </value>
        </row>
        <row>
            <value>37</value>
            <value>33</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>&#x2003;Women (N=5,404) age 22-29 present at the 4-year study visit of the Costa Rica Vaccine Trial
                provided a vulvar and cervical sample. A subset (N=1,044) was tested for HPV DNA (SPF10/LiPA25 version
                1); this comprised our intention-to-treat analytic cohort. VE against one-time detection of vulvar
                HPV16/18 among HPV vaccinated versus unvaccinated women was calculated and compared to VE at the cervix.
                Prevalence of and risk factors for vulvar (and cervical) HPV were evaluated in the control arm (N=536).
            </value>
        </row>
        <row>
            <value>38</value>
            <value>33</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>&#x2003;Vulvar HPV16/18 VE (54.1%; 95%CI:4.9%-79.1%) was comparable to cervix (45.8%
                95%CI:6.4%-69.4%). Prevalence of vulvar and cervical HPV16 within the control arm was 3.0% and 4.7%,
                respectively. Independent risk factors for vulvar HPV were similar to cervix and included: age (adjusted
                odds ratio [adjOR] 0.5 [95%CI:0.3-0.9] women &#x2265;28 versus 22-23]); marital status (adjOR 2.3
                [95%CI:1.5-3.5] single versus married/living-as-married); and number of sexual partners (adjOR 3.6
                [95%CI:1.9-7.0] &#x2265;6 versus 1).
            </value>
        </row>
        <row>
            <value>39</value>
            <value>33</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>&#x2003;In this intention-to-treat analysis, VE against prevalent vulvar HPV16/18 4-years following
                vaccination was comparable to that observed at the cervix. Risk factors for HPV were similar by anatomic
                site.
            </value>
        </row>
        <row>
            <value>40</value>
            <value>34</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Different treatment options are available for patients with gynecological cancers. Imaging plays an
                important role in assessment of patients with common cancers involving uterine body, cervix and ovaries,
                from detection to evaluation of the extent of disease. The purpose of this review is to highlight the
                role of cross-sectional imaging techniques in treatment stratification and overall management of
                patients with endometrial, cervical and ovarian cancers. Several imaging techniques used are described,
                including ultrasound, computed tomography (CT), MRI and&#xA0;PET/CT. Specific imaging appearances of the
                most common uterine, cervical and ovarian cancers are discussed. Imaging findings corresponding to the
                2009 revised International Federation of Gynecology and Obstetrics (FIGO) staging of gynecologic
                malignancies are also described. In the multidisciplinary evaluation of patients with gynecologic
                malignancies, the role of the radiologist has become central for accurate diagnosis and evaluation of
                extent of disease to achieve better treatment selection and planning.
            </value>
        </row>
        <row>
            <value>41</value>
            <value>35</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Farmers and farm workers have previously been found to experience decreased risk of some causes of
                death but elevated risks of certain types of cancer. A previous report on cancer incidence in a farm
                worker labor union between 1987 and 1997 found increased leukemia, brain, stomach, and uterine cervix
                cancer rates in this working population.
            </value>
        </row>
        <row>
            <value>42</value>
            <value>35</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>A roster of farm workers was created and electronically linked to the database of the California
                Cancer Registry. Proportionate cancer incidence (PCIR), stage, and age at diagnosis and histological
                subtypes of cancer were compared between the United Farm Workers (UFW) members and the Hispanic
                population of California as well as to the non-Hispanic whites (NHW).
            </value>
        </row>
        <row>
            <value>43</value>
            <value>35</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>In this population of 139,000 farm workers in California, more than 3,600 cancer diagnoses were
                recorded between 1988 and 2010. Proportionately more cancer was noted in the UFW than among California
                NHW for kidney and renal pelvis cancer (PCIR&#x2009;=&#x2009;1.60), liver (PCIR&#x2009;=&#x2009;4.24),
                prostate (PCIR&#x2009;=&#x2009;1.13), and uterine cervix cancer (PCIR&#x2009;=&#x2009;2.08).
                Proportionately less breast (PCIR&#x2009;=&#x2009;0.85), lung (PCIR&#x2009;=&#x2009;0.75), skin melanoma
                (PCIR&#x2009;=&#x2009;0.18), and urinary bladder cancer (PCIR&#x2009;=&#x2009;0.59) was found. Stage at
                diagnosis was more advanced in the farm workers for several cancer sites, although, not for colorectal
                cancer.
            </value>
        </row>
        <row>
            <value>44</value>
            <value>35</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>These farm workers experience proportionally more prostate, kidney and renal pelvis, brain, liver,
                stomach, cervix and leukemia and less breast, melanoma, and colorectal cancer than reference
                populations. For many sites, cancer is not diagnosed as early in the farm workers as in the comparison
                groups, except for colorectal cancer in females and melanoma in males. Am. J. Ind. Med. 57:737-747,
                2014. &#xA9; 2014 Wiley Periodicals, Inc.
            </value>
        </row>
        <row>
            <value>45</value>
            <value>36</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Labor resembles an inflammatory response that includes secretion of cytokines/chemokines by resident
                and infiltrating immune cells into reproductive tissues and the maternal/fetal interface. Untimely
                activation of these inflammatory pathways leads to preterm labor, which can result in preterm birth.
                Preterm birth is a major determinant of neonatal mortality and morbidity; therefore, the elucidation of
                the process of labor at a cellular and molecular level is essential for understanding the
                pathophysiology of preterm labor. Here, we summarize the role of innate and adaptive immune cells in the
                physiological or pathological activation of labor. We review published literature regarding the role of
                innate and adaptive immune cells in the cervix, myometrium, fetal membranes, decidua and the fetus in
                late pregnancy and labor at term and preterm. Accumulating evidence suggests that innate immune cells
                (neutrophils, macrophages and mast cells) mediate the process of labor by releasing pro-inflammatory
                factors such as cytokines, chemokines and matrix metalloproteinases. Adaptive immune cells (T-cell
                subsets and B cells) participate in the maintenance of fetomaternal tolerance during pregnancy, and an
                alteration in their function or abundance may lead to labor at term or preterm. Also, immune cells that
                bridge the innate and adaptive immune systems (natural killer T (NKT) cells and dendritic cells (DCs))
                seem to participate in the pathophysiology of preterm labor. In conclusion, a balance between innate and
                adaptive immune cells is required in order to sustain pregnancy; an alteration of this balance will lead
                to labor at term or preterm.Cellular &amp;amp; Molecular Immunology advance online publication, 23 June
                2014; doi:10.1038/cmi.2014.46.
            </value>
        </row>
        <row>
            <value>46</value>
            <value>37</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Six novel 5,6-fused hybrids such as dihydrobenzofuran-quinone (4a and 4b), benzofuran-quinone (5a and
                5b) and chromene-quinone (6a and 6b) of juglone based 1,4-naphthoquinones were synthesized by employing
                a three step protocol with the cyclisation of o-allyl phenol as the key step. The anticancer activity of
                the newly synthesized compounds was evaluated in&#xA0;vitro against seven human cancer cell lines
                including cervix (ME-180 and HeLa), breast (MCF-7, MDA-MB-453 and MDA-MB-231), prostate (PC-3) and colon
                (HT-29) by using MTT assay. The screening results showed that majority of the synthesized compounds
                exhibited significant anticancer activity. In particular, compounds 6a and 6b showed potent activities
                than the standard drug etoposide against prostate and breast cancer cell lines respectively. Flow
                cytometric analysis revealed that compounds 6a and 6b induced apoptosis and arrested the cell cycle at
                G2/M phase in PC-3 and MDA-MB-453 cells respectively.
            </value>
        </row>
        <row>
            <value>47</value>
            <value>38</value>
            <value>1</value>
            <value>Aim</value>
            <value>Objective</value>
            <value>The aim of this study was to study whether FDG was uniformly distributed throughout the skeleton and
                whether age and gender affected this biodistribution.
            </value>
        </row>
        <row>
            <value>48</value>
            <value>38</value>
            <value>2</value>
            <value>Material and methods</value>
            <value>Methods</value>
            <value>A total of 158 patients were included in this retrospective study. None of the patients had received
                prior treatment that had affected the bone marrow and patients with bone metastases, trauma, benign
                and/or malignant hematologic disorders were excluded from the study. The SUVmax from the 24 different
                locations in the skeleton was obtained and all the values were compared with each other.
            </value>
        </row>
        <row>
            <value>49</value>
            <value>38</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>FDG uptake in the skeleton was not uniform in both sexes. While the highest FDG uptake was seen in
                the L3 vertebra, the lowest glucose metabolism was observed in the diaphysis of the femur. Concerning
                the vertebral column, FDG uptakes were also non-uniform and the SUVmax gradually increased from the
                cervix to the lumbar spine. The mean skeletal SUVmax was decreased in accordance with age in both
                genders.
            </value>
        </row>
        <row>
            <value>50</value>
            <value>38</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>FDG was not uniformly distributed throughout the skeleton in both sexes. It had a tendency to
                increase from the appendicular to axial skeleton and from cervical to lumbar spine in the vertebral
                column that may be related with the normal distribution of the red bone marrow. Additionally, the
                glycolytic metabolism of the whole skeleton was gradually decreased in accordance with the age in both
                sexes.
            </value>
        </row>
        <row>
            <value>51</value>
            <value>39</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Pyometra is a reproductive disorder very common in bitches over 8&#xA0;years of age in which
                physiological effects of progesterone on the uterus play a major role. The traditional therapy for
                pyometra is ovariohysterectomy. The main advantage of ovariohysterectomy over medical management is that
                it is both curative and preventive for recurrence of pyometra. However, surgery is associated with the
                risk of anaesthesia and renders the bitch sterile. During the last 10&#xA0;years, numerous medical
                treatments have been proposed to treat both open and closed cervix pyometra. The most effective medical
                treatment with minor side effects seems to be the repeated administration of aglepristone with or
                without the additional treatment with low doses of prostaglandins.
            </value>
        </row>
        <row>
            <value>52</value>
            <value>40</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Context: Cancer data from Rajasthan is limited. Only three studies, one from Western Rajasthan, and
                the other two from Eastern Rajasthan have been published previously. Aims: To find out the spectrum of
                malignant neoplasms in Jaipur region by studying the proportion and site wise distribution of malignancy
                cases reported at five major hospitals and pathology centers in Jaipur region. Settings and Design: A
                retrospective analysis of histopathology records of 5 years (2004-2008) was done. Approximately 200,000
                histopathology and cytology reports were analyzed and 34,486 new cancer cases were identified.
                Statistical Analysis Used: Percentages and proportions. Results: A total of 34,486 new cases of cancers
                were recorded in five years. There were 58.58% (20202) males and 41.42% (14284) females, with the male
                to female ratio being 1.41:1. Organ wise, Lung (13.25%), Larynx (5.35%), Oropharynx (5.09%), Brain
                (4.84%), Tongue (4.62%) and Prostate (4%) were the most common sites involved in males, whereas Breast
                (25.6%), Cervix (10.26%), Ovary (5.4%), Brain (3.68%), Esophagus (3.4%), Lung (3.01%) and Gall Bladder
                (2.35%) were common sites for malignancies in females. Conclusions: Significant findings were, a higher
                frequency of tobacco related cancers i.e., Lung cancer and Head and neck cancer in males, and screening
                detectable cancers (Breast and Cervix) in females. A higher frequency of Lung cancer in females was also
                noted as compared to previous studies. An unusually high frequency of Gall Bladder Cancers especially
                among the female population in this region is also a cause of concern. Our data was compared with the
                national data.
            </value>
        </row>
        <row>
            <value>53</value>
            <value>41</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Thyroid cancer is one of the most common endocrine disorders in the world. In India, about 42 million
                people suffer from various thyroid disorders. However, based on population-based cancer registry (PBCR)
                and Chennai cancer registry, thyroid cancer is emerging as a common cancer particularly in Chennai.
                Papillary thyroid carcinoma is considered as the most prevalent cancer constituting about 80-85&#xA0;%
                of thyroid malignancies. Rearranged during transfection (RET)/papillary thyroid carcinoma (PTC) gene
                rearrangements are one of the major genetic alterations found in papillary thyroid carcinoma. This
                present study aims at estimating the frequency of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai
                population and investigating the correlation between RET/PTC gene expressions with clinical parameters.
                Formalin-fixed paraffin-embedded (FFPE) tumor tissues obtained from 30 patients with papillary thyroid
                carcinoma were analyzed. Initially, to differentiate classic and follicular variants of papillary
                thyroid carcinoma samples, immunohistochemistry was performed. Thereafter, total RNA was isolated, and
                quantitative evaluation of RET/PTC1 and RET/PTC3 gene rearrangements by real-time PCR was performed.
                Chi-square test was performed to understand the correlation between positive and negative mutations of
                RET/PTC messenger RNA (mRNA) expression with clinical parameters. RET/PTC3 gene rearrangements were
                identified in 26/30 (86.67&#xA0;%) cases, and none of the patient in our series had RET/PTC1 gene
                rearrangements. There was no statistically significant difference observed between positive and negative
                mutations of RET/PTC3 mRNA expression with clinic pathological parameters. Our results indicate that
                RET/PTC3 gene rearrangements are the most prevalent form of rearrangements in PTCs of Chennai
                population.
            </value>
        </row>
        <row>
            <value>54</value>
            <value>42</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Although generally the prognosis of differentiated thyroid carcinoma (DTC) is good, approximately 5%
                of people are likely to develop metastases which fail to respond to radioactive iodine, and other
                traditional therapies, exhibiting a more aggressive behavior. Nowadays, therapy is chosen and
                implemented on a watch-and-wait basis for most DTC patients. Which regimen is likely to work best is
                decided on the basis of an individual's clinical information, but only data referring to outcomes of
                groups of patients are employed. To predict the best course of therapy, an individual patient's biologic
                data is rarely employed in a systematic way. Anyway, the use of not expensive individual genomic
                analysis could lead us to a new era of patient-specific and personalized care. Recently, key targets
                that are now being evaluated in the clinical setting have been evidenced in the pathogenesis of these
                diseases. Some of the known genetic alterations playing a crucial role in the development of thyroid
                cancer include B-Raf gene mutations, rearranged during transfection/ papillary thyroid carcinoma gene
                rearrangements, and vascular endothelial growth factor receptor-2 angiogenesis pathways. The development
                of targeted novel compounds able to induce clinical responses and stabilization of disease has overcome
                the lack of effective therapies for DTC, which are resistant to radioiodine and thyroid stimulating
                hormone-suppressive therapy. Interestingly, the best responses have been demonstrated in patients
                treated with anti-angiogenic inhibitors such as vandetanib and XL184 in medullary thyroid cancer, and
                sorafenib in papillary and follicular DTC.
            </value>
        </row>
        <row>
            <value>55</value>
            <value>43</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Background: The accurate diagnosis of benign and malign thyroid tumors is very important for the
                clinical management of patients. The distinction of thyroid papillary carcinoma follicular variant and
                follicular adenoma can be difficult. Aim: To investigate the alternative methods like
                immunohistochemistry and exon 15 in the BRAF gene 1799 T/A mutation analyses for distinguishing thyroid
                tumors. Materials and Methods: We applied immunohistochemical markers; CK19, HMWCK, Galectin-3, HBME-1
                and Fibronectin and mutant allele-specific PCR amplification technique was used to determine 1799 T/A
                mutation within the BRAF gene. Formalin-fixed parafin embedded tissues from 45 surgically total resected
                thyroids, included 26 thyroid papillary carcinoma follicular variant (FV-TPC), 8 Follicular Adenoma
                (FA), 6 Minimal invasive follicular carcinoma (MIFC) and 5 Follicular Carcinoma (FC). Statistical
                Analyses Used: Pearson Chi-Square and Kruskal Wallis tests were performed. Results: There was a positive
                correlation between FV-TPC and HMWCK, CK 19, HBME1, Galectin 3, fibronectin (P &lt; 0.05), but there was
                no correlation with FV-TPC and BRAF gene mutation (P &gt; 0.05). HBME-1 and CK 19 stained strong and
                diffuse positive in FV-TPCs but weak and focal in FAs. Conclusion: Our study suggests that morphologic
                features combined with immunohistochemical panel of HMWCK, CK19, HBME-1, Galectin-3 and fibronectin can
                help to distinguish benign and malign thyroid neoplasms and FV-TPC from follicular adenomas. BRAF gene
                1799 T/A mutation has been non-specific but its detection can be a useful tool combined with
                immunohistochemistry for diagnosing FV-TPC.
            </value>
        </row>
        <row>
            <value>56</value>
            <value>44</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>The double presentation of breast cancer and follicular lymphoma is extremely rare, and only six
                cases have previously been reported in the literature. In the present study, a case of synchronous
                ductal carcinoma in situ (DCIS) of the breast and follicular lymphoma is reported. During an annual
                breast screening procedure, a 49-year-old female presented with a hard induration under the nipple of
                the right breast and swelling of a soft lymph node (LN) in the right axilla. Mammography and
                ultrasonography revealed two lesions in the right breast: One was a tumor with microcalcification, 1.0
                cm in diameter, and the other was a large, crude calcification, 2.5 cm in diameter. In addition,
                computed tomography and positron emission tomography revealed swellings of the bilateral axillary (Ax)
                LN and intra-abdominal para-aortic LN. The patient underwent excisions of the large calcified mass, a
                micro-calcified tumor and the right AxLN. The pathological and immunohistochemical studies revealed fat
                necrosis and DCIS of the breast, which was positive for the estrogen receptor and the progesterone
                receptor, while human epidermal growth factor receptor II protein expression was evaluated as 2+ and
                stage was classified as pTis pN0 M0, stage 0. Furthermore, the Ax node was diagnosed as follicular
                lymphoma, which was positive for cluster of differentiation (CD)20, CD79a, CD10 and B-cell lymphoma
                (Bcl)-2 protein, but negative for Bcl-6 protein. The clinical stage was classified as stage III. The
                patient was administered chemotherapy followed by radiotherapy to the conserved breast. Two years have
                passed since the surgery, and the patient is disease-free.
            </value>
        </row>
        <row>
            <value>57</value>
            <value>45</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>The development of a second primary cancer after treatment of the first with radiotherapy or
                chemotherapy is well documented. Multiple metachronous primary cancers are known to occur in an
                individual, but it is often seen with hematological malignancies of childhood. The prevalence of
                multiple primary malignancies (MPM) is between 0.73% and 11.7%. The most frequent malignant associations
                are ovary-colon, ovary-breast, and breast-breast. The possibility of developing a second metachronous
                cancer 5 years after undergoing treatment of the initial head and neck cancer is approximately 22%.
                Here, we report two cases of multiple metachronous malignancies in head and neck region. A 46-year-old
                woman presented with thyroid and salivary gland neoplasms metachronously and another 21-year-old woman
                with Hodgkin' s Lymphoma, mucoepidermoid carcinoma of salivary Gland, and follicular variant of
                papillary carcinoma of thyroid.
            </value>
        </row>
        <row>
            <value>58</value>
            <value>46</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Background:This study aimed to identify novel biomarkers for thyroid carcinoma diagnosis and
                prognosis.Methods:We have constructed a human single-chain variable fragment (scFv) antibody library
                that was selected against tumour thyroid cells using the BRASIL method (biopanning and rapid analysis of
                selective interactive ligands) and phage display technology.Results:One highly reactive clone, scFv-C1,
                with specific binding to papillary thyroid tumour proteins was confirmed by ELISA, which was further
                tested against a tissue microarray that comprised of 229 thyroid tissues, including: 110 carcinomas (38
                papillary thyroid carcinomas (PTCs), 42 follicular carcinomas, 30 follicular variants of PTC), 18 normal
                thyroid tissues, 49 nodular goitres (NG) and 52 follicular adenomas. The scFv-C1 was able to distinguish
                carcinomas from benign lesions (P=0.0001) and reacted preferentially against T1 and T2 tumour stages
                (P=0.0108). We have further identified an OTU domain-containing protein 1, DUBA-7 deubiquitinating
                enzyme as the scFv-binding antigen using two-dimensional polyacrylamide gel electrophoresis and mass
                spectrometry.Conclusions:The strategy of screening and identifying a cell-surface-binding antibody
                against thyroid tissues was highly effective and resulted in a useful biomarker that recognises
                malignancy among thyroid nodules and may help identify lower-risk cases that can benefit from
                less-aggressive management.British Journal of Cancer advance online publication, 17 June 2014;
                doi:10.1038/bjc.2014.331 www.bjcancer.com.
            </value>
        </row>
        <row>
            <value>59</value>
            <value>47</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Objective: The expanding use of 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG-PET) has
                contributed to an increasing number of thyroid incidentalomas. The present study aims to estimate the
                prevalence of 18F-FDG-PET thyroid incidentalomas and to evaluate the clinicopathological features of
                thyroid malignancies detected by 18F-FDG-PET.Methods: Revision of all 18F-FDG-PET exams performed at the
                Portuguese Institute of Oncology, Lisbon, between 2007 and 2012 (n=9374). The inclusion criteria were
                focal thyroid uptake and absence of known thyroid disease.Results: Focal thyroid uptake was observed in
                60 out of 9374 18F-FDG-PET exams (prevalence of 0.64%). Fine-needle aspiration cytology (FNAC) was
                performed in 23 patients and reported as malignant in 14 cases (56.5% primary thyroid carcinoma; 4.3%
                secondary malignancy), as benign in 7 cases (30.5%) and as follicular lesion of undetermined
                significance in 2 cases (8.7%).Fourteen patients had surgery. A final histological diagnosis of
                papillary thyroid carcinoma was established in 12 cases (52.2%). Three were multifocal (25.0%); 8 had
                extrathyroidal extension (66.7%); 5 had angioinvasion (41.7%); 3 had lymph nodes metastases (25.0%) and
                2 showed lung metastases (16.7%). Overall, 91.7% were classified as intermediate or high risk. All
                patients had radioiodine therapy. At the last observation (mean follow-up was 29.9 months), persistent
                or recurrent disease was identified in 4 patients (33.3%) and none died from thyroid
                malignancy.Conclusions: Thyroid carcinomas disclosed by 18F-FDG-PET are associated with aggressive
                histological criteria likely to carry a worse prognosis.
            </value>
        </row>
        <row>
            <value>60</value>
            <value>48</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is highly
                accurate in diagnosing mediastinal lymphadenopathies of lung cancer and benign disorders. However, the
                utility of EBUS-TBNA in the diagnosis of mediastinal lymphomas is unclear. The aim of this study was to
                determine the diagnostic value of EBUS-TBNA in patients with suspected lymphoma. Materials and Methods:
                Sixty-eight patients with isolated mediastinal lymphadenopathy and suspected of lymphoma were included
                in the study. EBUS-TBNA was performed on outpatients under moderate sedation. The sensitivity,
                specificity, negative predictive value and diagnostic accuracy of EBUS-TBNA were calculated. Results:
                Sixty-four patients were diagnosed by EBUS-TBNA, but four patients with non-diagnostic EBUS-TBNA
                required surgical procedures. Thirty-five (51.5%) patients had sarcoidosis, six (8.8%) had reactive
                lymphadenopathy, nine (13.3%) had tuberculosis, one (1.5%) had squamous cell carcinoma, two (2.9%) had
                sarcoma and fifteen (22%) had lymphoma (follicular center cell, large B-cell primary, and Hodgkin
                lymphomas in three, two, and ten, respectively). Of the 15 lymphoma patients, thirteen were diagnosed by
                EBUS and two by thoracotomy and mediastinoscopy. The sensitivity, specificity, negative predictive
                value, and diagnostic accuracy of EBUS-TBNA for the diagnosis of lymphoma were calculated as 86.7%,
                100%, 96.4%, and 97%, respectively. Conclusions: EBUS-TBNA can be employed in the diagnosis of
                mediastinal lymphoma, instead of more invasive surgical procedures.
            </value>
        </row>
        <row>
            <value>61</value>
            <value>49</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>There have only been a few reports of thyroid-like follicular carcinoma of the kidney (TLFCK) to
                date. In the present study, two patients with TLFCK are reported. Patient 1 was a 65-year-old male
                exhibiting repeated hematuria and right back pain. No tumors were located in the patient's thyroid or
                lungs. The physical examination revealed percussion tenderness over the right kidney region was noticed.
                Enhanced computed tomography (CT) indicated a right renal pelvic carcinoma, for which the patient
                underwent a radical right nephrectomy. Patient 2 was a 59-year-old male with a mass in the right kidney,
                located during a health examination and who exhibited no obvious clinical symptoms. The patient was
                clinically diagnosed with right renal carcinoma, confirmed by an enhanced CT. The patient underwent a
                radical right nephrectomy. The clinical features, imaging results, pathology, immune phenotypes,
                treatment and prognosis were analyzed. The associated literature was also reviewed. The cut surface of
                each tumor showed gray-white material with a central solid area, including scattered gray-brown necrotic
                and gray hemorrhagic areas and small cystic cavities. Microscopically, the arrangement of the tumor
                cells mimicked thyroid follicles with red-stained colloid-like material in the lumen. No renal hilar
                lymph node involvement was noted. The tumor tissue of patient 1 was immunohistochemically positive for
                vimentin, epithelial membrane antigen (EMA), cytokeratin (CK), CK7, and neuron specific enolase; and
                negative for CK34BE12, synapsin (Syn), CK20, cluster of differentiation 56 (CD56), CD10, Wilm's tumor-1
                (WT-1), CD34, CD57, P53, CD99, thyroid transcription factor-1 (TTF-1), CD15 and thyroglobulin (TG); with
                a Ki-67 labeling index (LI) of 30%. The tumor tissue of patient 2 was immunohistochemically positive for
                vimentin, EMA, CK7 and CK20; and negative for CD56, CD10, WT-1, CD34, CD57, P53, CD117, TTF-1, CD15,
                CD99, TG, chromogranin A and Syn; with a Ki-67 LI of 20%. TLFCK is a rare renal tumor with low
                malignancy but medium invasiveness. It morphologically resembles thyroid follicular carcinoma but does
                not express TTF-1 or TG. Radical nephrectomy can achieve good patient outcomes.
            </value>
        </row>
        <row>
            <value>62</value>
            <value>50</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>c-KIT/CD117 down-regulation has been described in papillary thyroid carcinoma (PTC). In this study,
                the authors investigated CD117 as an ancillary immunocytochemical test for PTC in fine-needle aspiration
                biopsy (FNAB).
            </value>
        </row>
        <row>
            <value>63</value>
            <value>50</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>The expression of CD117 was assessed in cytologic samples of histologically confirmed classic PTC (n&#x2009;=&#x2009;35)
                and in a control group of benign thyroid nodules (BTNs) (n&#x2009;=&#x2009;30) using
                immunocytochemistry. The corresponding PTCs and BTNs from surgical resection specimens also were
                evaluated immunohistochemically for CD117. The expression of CD117 was assessed semiquantitatively using
                a scoring system from 0 to 5 that combined the proportion and the intensity of staining.
            </value>
        </row>
        <row>
            <value>64</value>
            <value>50</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>The difference in immunoreactivity for CD117 between PTC and BTNs was highly significant both in FNAB
                samples and in the corresponding histology samples (P&#x2009;&lt;&#x2009;.0001). On cytology, most PTCs
                (74%; n&#x2009;=&#x2009;26) lacked immunoreactivity for CD117, and 9 samples (26%) had faint reactivity
                in &lt;2% of tumor cells (score, 0). In contrast, all BTNs (100%; n&#x2009;=&#x2009;30) were positive
                for CD117, and at least 50% of the cells (score, 2-4) were positive in 79% (n&#x2009;=&#x2009;24) of
                BTNs. Results with corresponding histology were similar to the cytology results; most PTCs (89%; n&#x2009;=&#x2009;31)
                lacked immunoreactivity for CD117, and 4 samples (11%) had faint reactivity in &lt;2% of tumor cells. In
                contrast, all BTNs (n&#x2009;=&#x2009;30) were variably positive for CD117 (score, 2-4). Normal
                follicular epithelium also was positive for CD117 (score, 2-4).
            </value>
        </row>
        <row>
            <value>65</value>
            <value>50</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>CD117 is expressed in both normal follicular epithelium and in BTNs. In contrast, expression of CD117
                is absent or weak in PTC. These results suggest that CD117 may be useful as an ancillary marker for PTC.
                Cancer (Cancer Cytopathol) 2014 &#xA9; 2014 American Cancer Society.
            </value>
        </row>
    </table>
    <table name="users">
        <column>id</column>
        <column>email</column>
        <column>first_name</column>
        <column>middle_name</column>
        <column>last_name</column>
        <column>name</column>
        <column>created_on</column>
        <column>last_logged_in</column>
        <row>
            <value>1</value> <!-- id -->
            <value>dr.vikramraj87@gmail.com</value> <!-- email -->
            <value>Vikram Raj</value> <!-- first_name -->
            <value></value> <!-- middle_name -->
            <value>Gopinathan</value> <!-- last_name -->
            <value>Vikram Raj Gopinathan</value> <!-- name -->
            <value>2014-06-15 10:15:00</value> <!-- created_on -->
            <value>2014-06-17 02:35:00</value> <!-- last_logged_in -->
        </row>
        <row>
            <value>2</value> <!-- id -->
            <value>kirthiviswanath@gmail.com</value> <!-- email -->
            <value>Kirthika</value> <!-- first_name -->
            <value></value> <!-- middle_name -->
            <value>Viswanathan</value> <!-- last_name -->
            <value>Kirthika Viswanathan</value> <!-- name -->
            <value>2014-06-15 10:15:00</value> <!-- created_on -->
            <value>2014-06-17 02:35:00</value> <!-- last_logged_in -->
        </row>
    </table>
    <table name="collections">
        <column>id</column>
        <column>user_id</column>
        <column>name</column>
        <column>created_on</column>
        <column>updated_on</column>
        <row>
            <value>1</value>
            <value>1</value>
            <value>PowerOfTwo</value>
            <value>2014-06-20 14:01:03</value>
            <null/>
        </row>
        <row>
            <value>2</value>
            <value>1</value>
            <value>Even</value>
            <value>2014-06-20 20:20:20</value>
            <value>2014-06-24 18:03:52</value>
        </row>
        <row>
            <value>3</value>
            <value>2</value>
            <value>Odd</value>
            <value>2014-06-21 15:12:40</value>
            <null/>
        </row>
        <row>
            <value>4</value>
            <value>1</value>
            <value>Empty</value>
            <value>2014-06-25 15:12:40</value>
            <null/>
        </row>
    </table>
    <table name="collection_articles">
        <column>collection_id</column>
        <column>article_id</column>
        <column>position</column>
        <row>
            <value>1</value>
            <value>1</value>
            <value>1</value>
        </row>
        <row>
            <value>1</value>
            <value>2</value>
            <value>2</value>
        </row>
        <row>
            <value>1</value>
            <value>4</value>
            <value>3</value>
        </row>
        <row>
            <value>1</value>
            <value>8</value>
            <value>4</value>
        </row>
        <row>
            <value>1</value>
            <value>16</value>
            <value>5</value>
        </row>
        <row>
            <value>1</value>
            <value>32</value>
            <value>6</value>
        </row>
        <row>
            <value>2</value>
            <value>2</value>
            <value>1</value>
        </row>
        <row>
            <value>2</value>
            <value>4</value>
            <value>2</value>
        </row>
        <row>
            <value>2</value>
            <value>6</value>
            <value>3</value>
        </row>
        <row>
            <value>2</value>
            <value>8</value>
            <value>4</value>
        </row>
        <row>
            <value>2</value>
            <value>10</value>
            <value>5</value>
        </row>
        <row>
            <value>2</value>
            <value>12</value>
            <value>6</value>
        </row>
        <row>
            <value>2</value>
            <value>14</value>
            <value>7</value>
        </row>
        <row>
            <value>2</value>
            <value>16</value>
            <value>8</value>
        </row>
        <row>
            <value>2</value>
            <value>18</value>
            <value>9</value>
        </row>
        <row>
            <value>3</value>
            <value>25</value>
            <value>1</value>
        </row>
        <row>
            <value>3</value>
            <value>27</value>
            <value>2</value>
        </row>
        <row>
            <value>3</value>
            <value>29</value>
            <value>3</value>
        </row>
        <row>
            <value>3</value>
            <value>31</value>
            <value>4</value>
        </row>
        <row>
            <value>3</value>
            <value>33</value>
            <value>5</value>
        </row>
        <row>
            <value>3</value>
            <value>35</value>
            <value>6</value>
        </row>
        <row>
            <value>3</value>
            <value>37</value>
            <value>7</value>
        </row>
        <row>
            <value>3</value>
            <value>39</value>
            <value>8</value>
        </row>
    </table>
</dataset>
